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RÉSUMÉ 
 
Les cytokines pro-inflammatoires jouent un rôle important dans la pathogenèse de 
l’obésité et la stéatose hépatique. L'IL-15 est une cytokine pro-inflammatoire qui est  
trans-présentée par l'IL-15Rα aux chaines IL-2/IL-15Rβ et  γc. La fonction de l'IL-15 a été 
largement décrite dans les cellules immunitaires, mais ses fonctions dans d'autres tissus 
sont moins connues. Le but de ce mémoire est d'élucider le rôle de l'IL-15 dans la 
stéatose hépatique. 
Les souris C57BL/6 de type sauvage (WT) et Il15-/- ont été soumises à un régime 
hyperlipidique (HFD) ou à un régime normal. Après 16 semaines, le poids corporel, la 
masse hépatique, l'accumulation de lipides dans le foie, les taux de lipides sériques et 
l'expression des différents gènes reliés à l’inflammation et au métabolisme dans le foie 
ont été évalués. Les lymphocytes intra-hépatiques (IHL) ont été également étudiés. Des 
hépatocytes primaires ont été stimulés avec IL-15, et  l'expression génique de 
chimiokines a été déterminée. Les populations de IHLs ont été également caractérisées 
chez les souris WT, Il15-/- et Il15ra-/-, ainsi que chez des souris dont la déficience dans 
l’expression d’IL-15Rα est ciblée aux macrophages ou aux hépatocytes. 
Nos résultats montrent que la déficience en IL-15 empêche l'accumulation de lipides dans 
le foie. Les taux de cholestérol et d’acides gras non estérifiés dans le sang étaient élevés 
chez les souris WT, mais pas chez les souris Il15-/- . L'expression hépatique des 
chimiokines Ccl2, Ccl5, Cxcl10 et des marqueurs de macrophages était augmentée chez 
les souris WT sous HFD, mais pas chez les souris Il15-/-. La stimulation des hépatocytes 
primaires avec l'IL-15 induit l'expression des gènes des chimiokines chez les hépatocytes 
WT, mais pas chez les  Il15ra-/-. En outre, nous avons trouvé une infiltration réduite des 
cellules NK et NKT dans le foie des souris déficientes en Il15ra-/- dans les hépatocytes, ce 
qui suggère que l'expression d’IL15Rα chez les hépatocytes est nécessaire au 
recrutement des cellules NK, NKT et / ou à leur maintien. 
En conclusion, nous proposons que l’IL-15 favorise l'accumulation de lipides dans le foie, 
et que ceci est associée à une réponse inflammatoire accrue. La disponibilité accrue de 
l'IL-15 dans l'obésité pourrait stimuler les hépatocytes à secréter des chimiokines ce qui 
favorise l'inflammation hépatique et conduirait à la stéatose hépatique. L’expression de 
l'IL-15Rα dans les hépatocytes semble jouer un rôle principal dans l’infiltration des 
cellules NK, NKT et iNKT dans le foie. 
 
Mots clés : Stéatose hépatique non-alcoolique (NAFLD), lymphocytes intra-hépatiques 
(IHL), régime hyperlipidique (HFD), IL-15, chimiokines, inflammation, IL-15Rα.  
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ABSTRACT 
Pro-inflammatory cytokines play a key role in pathogenesis of obesity and non-
alcoholic fatty liver disease (NAFLD). IL-15 is a pro-inflammatory cytokine, which 
signals through a receptor complex composed of the IL-15 receptor (IL-15R) alpha 
chain, the IL-2/IL-15R beta chain and the common gamma chain. The functions of IL-
15 have been extensively described in immune cells but less is known about its 
functions in others tissues such as the liver. The aim of this thesis is to investigate the 
role of IL-15 in fatty liver disease. 
C57BL/6 wildtype (WT) and IL-15 knockout (Il15-/-) mice were maintained on high fat 
diet (HFD) or normal control diet (NCD). After 16 weeks, body weight, liver mass, fat 
accumulation in the liver, serum lipid levels and gene expression in the liver were 
evaluated. Intrahepatic lymphocytes (IHL) were also analysed. Primary hepatocytes 
were stimulated with IL-15 and chemokines gene expression was studied. IHLs were 
examined in WT, Il15-/- and Il15ra-/-, as well as in macrophage- and hepatocyte-specific 
Il15ra-/- mice. 
We found that IL-15 deficiency prevents weight gain and accumulation of lipids in the 
liver. Circulating levels of cholesterol and non-esterified fatty acids were elevated in 
WT mice but not in Il15-/- mice. Hepatic expression of chemokines such as Ccl2, Ccl5 
and Cxcl10 was increased in WT mice under HFD, but not in Il15-/- mice. The livers of 
Il15-/- and  Il15ra-/- mice also showed decreased expression of Tnfa and iNOS, and 
macrophage markers Cd68 and F4/80. Accordingly, stimulation of primary hepatocytes 
with IL-15 induced chemokine gene expression in WT but not in Il15ra-/- hepatocytes. 
Furthermore, hepatocyte-specific ablation of IL-15Rα reduced infiltration of NK and 
NKT cells in the liver, suggesting that IL15Rα expression in the hepatocytes is needed 
for the recruitment and/or maintenance of the NK cell population in the liver.  
In conclusion, IL-15 promotes fat accumulation in the liver, and this is associated with 
increased inflammatory response in the liver. Increased availability of IL-15 in obesity 
may stimulate hepatocytes to secrete chemokines that promote hepatic inflammation 
resulting in fatty liver disease. IL-15Rα expression in hepatocytes appears to play a 
role in the maintenance of NK, NKT and iNKT cells. 
 
Keywords: non-alcoholic fatty liver disease (NAFLD), intra-hepatic lymphocytes (IHL), 
high fat diet (HFD), IL-15, chemokines, inflammation, IL-15Rα.  
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1. INTRODUCTION 
1.1. Structure and functions of the liver 
1.1.1. Structure of the liver  
Liver is one of the most important metabolic organs in the body and plays a central role in 
the synthesis of many plasma proteins and carbohydrates, storage of minerals and 
vitamins and detoxifying toxins that enter portal vein circulation (Fausto, N. et al., 2006). 
Liver cells are classified into two main groups: epithelial cells and mesenchymal cells. In 
the epithelial cells group, the major subtype is hepatocytes, which represents more than 
90% of the liver parenchyma (Papoulas, M. and Theocharis, S., 2009). Cholangiocytes 
also belong to this group, and are located in the intra-hepatic and extra-hepatic biliary duct 
system. Moreover, cholangiocytes release bicarbonate and water, which modifies the bile 
produced by hepatocytes (O'Hara, S.P. et al., 2013). Hepatic non-parenchymal cells 
include endothelial cells, Kupffer cells (KCs), lymphocytes, hepatic stellate cells (HSCs) 
and biliary ductal cells (Lemoinne, S. et al., 2013). KCs reside in liver sinusoids and are 
derived from circulating monocytes. They constitute approximately 20% of hepatic non-
parenchymal cells (Ruck, P. and Xiao, J.C., 2002) 
Hepatic stellate cells produce hepatocyte growth factor (HGF), store retinoids and serve 
as precursors of liver myofibroblasts (Friedman, S.L., 2008). Myofibroblasts are the main 
fibrogenic effector cells and are absent in the healthy liver. However, following liver 
damage, HSCs differentiate and start producing extracellular matrix and collagen 
(Lemoinne, S. et al., 2013). Liver sinusoidal endothelial cells (LSEC) line the capillaries 
and sinusoids and differ from the endothelium of big vessels in lacking basement 
membrane and containing the fenestrae structures. Moreover, a subset of LSECs is 
derived from the bone marrow and, like HSCs, is one of the main sources of HGF 
(DeLeve, L.D., 2013).  Liver lymphocytes are primarily located around the portal tracts. 
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This distribution of lymphocytes in the liver aids in the rapid removal of gastrointestinal 
antigens from the circulation (Zhan, Y.T. and An, W., 2010). 
 
1.1.2. Metabolic functions of the liver 
Liver is a major metabolic organ in the body and plays important roles in protein, 
carbohydrate and lipid metabolic pathways.  
In proteins metabolism, liver participates in amino acids degradation to supply both, 
carbohydrates and fatty acids (FAs) metabolic pathways, and protein synthesis. In the 
human serum, the most abundant protein is albumin, which is synthetized by hepatocytes 
and represents the 15 percent of the total hepatic protein synthesis.  Albumin’s half-life of 
is around 20 days, so that a decrease in serum albumin is unlikely to occur within a short 
time of acute liver injury. In patients with ascites and chronic liver disease the serum level 
of albumin is often low (Rothschild, M.A. et al., 1969). Various coagulation factors such as 
II, VII, IX, X, V, XI, XII, and XIII and fibrinogen are synthesized in the liver. As coagulation 
factors have short life-span, defects in coagulation quickly become apparent in acute liver 
damage. Some inhibitors of coagulation and fibrinolysis are also synthesized in the liver. 
Moreover, in liver disease, the prolongation of prothrombin time results from a deficiency 
in factors II, V, VII, and X; and can be used as a predictive factor of acute liver failure 
(Aranha, G.V. and Greenlee, H.B., 1986). Transamination and oxidative deamination of 
amino acids takes place in the hepatocytes and leads to nitrogenous excretory products, 
which enter in the Krebs-Henseleit cycle producing urea (Zieve, L., 1979). 
In carbohydrates metabolism, liver regulates glucose levels in the blood by controlling 
glucose uptake after meals and releasing glucose during fasting. Carbohydrate 
metabolism in the liver is proportional to the degree of hypoglycemia or hyperglycemia. In 
hypoglycemic condition, glucose synthesis from endogenous sources is increased, for 
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example, endogenous glycogen is catabolized into glucose that enters the blood (Stanley, 
J.C., 1981). This process is controlled by several hormones, such as catecholamines that 
stimulate the rate of gluconeogenesis via cyclic adenosine monophosphate (Fausto, N. et 
al.)-dependent (beta-mimetic) and cAMP-independent (alpha-mimetic) mechanisms 
(Hems, D.A. and Whitton, P.D., 1980). On the other hand, insulin antagonizes the action 
of both glucagon and catecholamines on hepatic gluconeogenesis.  
Fat containing chylomicrons reach the liver via lymph and the blood. Degradation of fat to 
acetyl coenzyme A (acetyl-CoA), a main step in the metabolic integration of different 
pathways, occurs in the liver. Acetyl-CoA can enter into the tricarboxylic acid cycle or 
participate in the synthesis of triglyceride phospholipid, cholesterol and lipoproteins. Fatty 
acids in the liver can be metabolized by esterification or oxidation. Glucagon markedly 
stimulates the rate of FA oxidation, whereas insulin inhibits it. The beta oxidation of FAs 
results in the production of acetyl-CoA in the mitochondria, where the acetyl-CoA is further 
oxidized to carbon dioxide and water or is converted to ketone bodies (Voet, J.G. and 
Voet, D., 2000).  
FA synthesis from excess glucose also occurs in the liver. FAs are esterified with glycerol 
in the liver to form triglycerides, which are then incorporated into lipoproteins, principally 
very-low-density lipoprotein (VLDL), that are secreted by the liver. The principal factor 
affecting VLDL production is the amount of free FAs reaching the liver. Secretion of VLDL 
is also stimulated by insulin (Kamagate, A. and Dong, H.H., 2008). Hepatic lipid synthesis 
is stimulated by insulin after food intake. Interestingly, in metabolic disease (insulin 
resistant state), liver and plasma triglycerides are increased. Different studies propose a 
model where distinct insulin signalling pathways independently modulate glucose and lipid 
metabolism (Brown, M.S. and Goldstein, J.L., 2008). In insulin-resistant subjects, whereas 
insulin fails to adequately augment hepatic glucose uptake or suppress hepatic glucose 
production, hepatic lipogenesis and triglycerides accumulation remain elevated and 
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contribute to hypertriglyceridemia. The major metabolic pathways disrupted in insulin 
resistance condition are: hepatic glucose uptake and glycogen deposition (impaired); 
gluconeogenesis and de novo lipogenesis (active) and FA delivery and triglyceride 
esterification and secretion (accelerated). The collective effects of these dysregulated 
pathways in multiple tissues precipitates the metabolic syndrome phenotype (Otero, Y.F. 
et al., 2014). 
 
1.1.3. Liver as part of the immune system 
Recent evidence suggests that liver can also be considered as part of the immune system 
as it plays a major role in innate immunity (Dong, Z. et al., 2007; Gao, B. et al., 2008). The 
innate immune system is the first barrier in the host defense during an infection. Innate 
immunity consists of innate lymphocytes, phagocytic cells, physical and chemical barriers 
and humoral factors. Between 80%-90% of innate protein biosynthesis takes place in the 
liver, for example acute-phase proteins (APPs), complement factors and secreted pattern 
recognition receptors. Complement system components are synthesized in the liver and 
represent about 5% of the globulin fraction of blood plasma. The complement system is 
involved in the development of many liver disorders, including liver fibrosis and alcoholic 
liver disease (Zhan, Y.T. and An, W., 2010). 
The proportion of innate immune cells is much higher in the liver compared to other 
organs such as spleen. Due to its anatomical location, liver immune cells are exposed to 
large amounts as well as a wide variety of antigens and toxins. KCs are the main 
phagocytic cells in the liver and constitute almost the 80%-90% of the total tissues 
macrophages in the body (Doherty, D.G. and O'Farrelly, C., 2000). As liver macrophages, 
KCs possess scavenger receptors that eliminate blood-borne pathogens and bacteria 
from blood stream (Lemoinne, S. et al., 2013). They also secrete pro-inflammatory 
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cytokines and reactive oxygen species (ROS) (Nagy, L.E., 2003). The immune response 
induced by these mediators promotes hepatocytes injury. Natural killers (NK) and natural 
killers T cells (NKT) cells are the major subsets of intra-hepatic lymphocytes and they 
account for 10%-30% in mouse and between 30%-50% in rat and human livers (Exley, 
M.A. and Koziel, M.J., 2004). 
The adaptive immune cells of the liver have been also studied, mostly in the context of 
viral infections. CD8+ T cells are the main effector cells that control viral infections via 
cytotoxic activity and cytokine secretion, as observed in acute hepatitis C virus infection 
(Sung, P.S. et al., 2014). It has also been reported that liver-resident memory CD8+ T 
cells are required for protection against liver-stage Plasmodium infection (Van Braeckel-
Budimir, N. and Harty, J.T., 2014). 
 
1.2. Obesity 
Sedentary lifestyle and increased energy intake are the major causes of obesity and the 
associated metabolic syndrome (Otero, Y.F. et al., 2014). Other contributing factors of 
obesity include genetic susceptibility, endocrine disorders, medications and psychiatric 
illnesses. The excessive accumulation of body fat also lead to decreased mobility and 
other obesity-associated pathologies that reduce life expectancy (Haslam, D.W. and 
James, W.P., 2005). Obesity is expressed as body mass index (BMI), a measurement 
obtained by dividing a person's weight by the square of the person's height. Values 
greater than 30 kg/m2 are considered overweight (WHO 2000, p.9).   
Obesity is characterized by altered glucose homeostasis, hyperinsulinemia and 
hypertriglyceridemia. Hyperinsulinemia is thought to be driven by the accompanying 
insulin resistance in multiple tissues including liver, muscle, adipose tissue, vasculature 
and the brain (Carey, M. et al., 2013). Furthermore, obesity leads to many co-morbidities, 
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particularly heart disease, hypertension, type 2 diabetes, obstructive sleep apnea, certain 
types of cancer, and osteoarthritis (Haslam, D.W. and James, W.P., 2005). For example, 
hypertension incidence is increased five-fold in obese patients compared to those with 
normal weight (Haslam, D.W. and James, W.P., 2005). Adipocytes from obese individuals 
secrete an angiotensin precursor, which increases blood pressure. Profibrinogen and 
plasminogen activator inhibitor 1 are also secreted by adipocytes and are responsible for 
the change in blood viscosity (Haslam, D.W. and James, W.P., 2005). 
The most common consequence of obesity is type 2 diabetes. Almost 90% of individuals 
who develop type 2 diabetes have an elevated BMI. There are others factors that increase 
the susceptibility of obese patients to develop diabetes, such as family history of diabetes, 
mothers who had gestational diabetes, age, etc. (Haslam, D.W. and James, W.P., 2005). 
Fat accumulation in different tissues leads to the development of tissue specific obesity-
associated pathologies.    
1.2.1. Obesity-associated inflammation 
Fat deposition in obesity is also characterized by increased infiltration of pro-inflammatory 
immune cells into adipose tissues causing chronic, low-grade inflammation (Sell, H. et al., 
2012). Adipose tissue dysfunction during obesity is a consequence of inflammatory 
response in the visceral compartment (Despres, J.P. and Lemieux, I., 2006). The link 
between obesity and inflammation remains unclear, and different mechanisms have been 
proposed. One of first hypotheses proposed is that macrophage infiltration is initiated 
following death of adipocytes as a consequence of increased production of chemokines 
and adipokines. During obesity, adipocyte hypertrophy results in necrosis-like death 
leading to increased macrophage recruitment. Cinti et al. report that these infiltrating 
macrophages form crown-like structures around necrotic adipocytes (Cinti, S. et al., 
2005). On the other hand, apoptosis, a physiological process during normal adipocyte 
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turnover leads to accumulation of M2-type macrophages, which are anti-inflammatory. 
(Sell, H. et al., 2012). Thus, the inflammation in the adipose tissues is determined by the 
fate of adipocytes.   
It has been suggested that the phenotype switching of the adipose tissue-associated  
macrophages from anti-inflammatory M2 type to pro-inflammatory M1 type plays a central 
role in obesity-associated inflammation (Sell, H. et al., 2012). The M2 macrophage 
population, predominantly anti-inflammatory, decreases during obesity with a concomitant 
increase in the pro-inflammatory M1 macrophages. The presence of M1 macrophages 
correlates with insulin resistance and states of over-nutrition (Lumeng, C.N. et al., 2007). 
A complex crosstalk between adipocytes, macrophages and other immune cells from both 
innate and adaptive immune systems results in adipose tissue inflammation (Sun, K. et 
al., 2011). 
 
1.3. Fatty liver diseases 
In developed countries, the increase in obesity is also related to the increased prevalence 
of non-alcoholic fatty liver disease (NAFLD). Fatty liver diseases progress from benign 
fatty changes to cirrhosis, portal hypertension, and hepatocellular carcinoma (Haslam, 
D.W. and James, W.P., 2005). Among fatty liver patients, 50% develop fibrosis, 30% 
cirrhosis, and 3% will develop liver failure and with a requirement for transplantation. Fatty 
liver is one of the most common causes of end-stage liver failure. The main predisposing 
factors to NAFLD are obesity, diabetes, hyperlipidemia, and hypertension. The disease is 
mainly asymptomatic.  The first clinical indication is the increase in the concentration of γ-
glutamyl transpeptidase and alanine aminotransferase, and to a lesser extent, aspartate 
aminotransferase and alkaline phosphatase (Haslam, D.W. and James, W.P., 2005). The 
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main treatment for NAFLD is weight reduction by regulated diet and physical activity, 
insulin sensitizers and medications that reduce oxidative stress (Tapia, N.C. et al., 2006). 
In 1998, Day et al., describe the pathogenesis of NAFLD as two-step pathology. Fat 
accumulation is considered the first one and makes the liver susceptible to the injurious 
effects of others factors, while the second one promotes the development of inflammation 
(NASH: non-alcoholic steatohepatitis) and fibrosis (Day, C.P. and James, O.F., 1998). 
These factors include cytokine overproduction, lipid peroxidation, hepatocyte organelle 
(particularly mitochondria) malfunction, ROS and peroxisome proliferator-activated 
receptor (PPAR) dysfunction in the nucleus (Zhan, Y.T. and An, W., 2010). 
In the context of insulin resistance, the development of NAFLD depends on the functional 
crosstalk between the liver and peripheral tissues, including the skeletal muscle and 
adipose tissues, but the underlying molecular mechanisms have not been fully elucidated. 
In insulin-resistant subjects, increased lipolysis in the adipose tissues increases the 
circulating free-FAs that are incorporated into hepatic triglyceride (Adams, L.A. et al., 
2005). De novo hepatic lipogenesis is also upregulated by the activation of several 
lipogenic transcription factors, including sterol regulatory element-binding protein 1c 
(SREBP1c) and carbohydrate response element binding protein (also known as MLXIPL). 
Insulin-mediated activation of SREBP1c promotes malonyl-CoA increase, which also 
inhibits FA oxidation (Browning, J.D. and Horton, J.D., 2004). 
Free-fatty acid toxicity has been partially explained by the endoplasmic reticulum (ER) 
stress and apoptosis, induced by metabolites, including ceramides and diacyglycerols. ER 
stress as well as serum-free FAs, cytokines, etc., can activate c-Jun N-terminal kinase 1 
(JNK1) (also known as MAPK8), which phosphorylates insulin receptor substrate 1 (IRS1) 
resulting in its inhibition and induces pro-inflammatory cytokines in target cells such as 
macrophages leading to insulin resistance (Smith, B.W. and Adams, L.A., 2011).  
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NASH and insulin resistance are extensively related to a cytokine imbalance towards pro-
inflammatory microenvironment in the liver. Even if NASH is not classically considered to 
be a T helper 1(Th1)-polarized disease, recent studies show that the increase in pro-
inflammatory Th1 cytokines and a decrease in anti-inflammatory cytokines can affect fatty 
liver disease progression (Li, Z. and Diehl, A.M., 2003; Maher, J.J. et al., 2008). 
FAs from the diet, adipose tissue lipolysis and intestinal bacteria activate toll-like receptors 
(TLRs) expressed on immune cells in the liver, resulting in the activation of innate immune 
system (Wolowczuk, I. et al., 2008). Moreover, the adipose tissue-derived cytokines can 
also activate immune cells in the liver. In NAFLD, KCs become activated by 
proinflammatory cytokines such as tumor necrosis factor-α (TNFα) (Fan, J. et al., 2001; 
Su, G.L., 2002), and their inactivation could prevent the development of alcoholic fatty 
liver and NAFLD (Zhan, Y.T. and An, W., 2010). Moreover, different cell types within the 
liver can promote each other in perpetuating the inflammatory response. For instance, 
KCs stimulate NK activity by direct interaction or indirectly through interleukin (IL)-12, IL-
18 and TNF-α (Hou, X. et al., 2009). 
Similarly to macrophages, KCs can switch from anti-inflammatory state (M2) to pro-
inflammatory activated (M1) phenotype. Activated KCs play an important role in the 
development of NAFLD by producing TNF-α, IL-12, IL-6, and ROS. Particularly, TNF-α 
exerts a principal role in the development of NAFLD. Thus anti-TNF-α treatment improves 
high fat diet-induced NAFLD (Li, Z. et al., 2003). Besides TNF-α, several other pro-
inflammatory cytokines have been studies in the context of NAFLD and insulin resistance. 
IL-6 is also implicated in promoting hepatic inflammation and fibrosis. Moreover, in the 
liver, IL-6 mediates insulin resistance while in the muscle it promotes the insulin-regulated 
glucose metabolism (Zhan, Y.T. and An, W., 2010). Another study showed that IL-6 
treatment is beneficial in NAFLD in mice, even though the mechanism is not clear (Hong, 
F. et al., 2004).   In addition to the proinflammatory cytokines, activated KCs also generate 
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ROS that promote insulin resistance and are believed to play an important role in the 
conversion of simple hepatic steatosis to NASH.  However, the molecular mechanisms 
involved in the production of ROS by KCs is not clear (Maher, J.J. et al., 2008).  
Transforming growth factor (TGF)-β1 secreted by KCs, hepatic stellate cells and 
sinusoidal endothelial cells, is one of the main fibrogenic factors in NASH (Zhan, Y.T. and 
An, W., 2010).  
Natural killer (NK) and NK cells expressing TCR (NKT) are implicated in the pathogenesis 
of fatty liver diseases. NK cells originate from the bone marrow and undergo a complex 
maturation process, resulting in the acquisition of their effector functions. They redistribute 
from the bone marrow and lymph nodes to blood, spleen, liver and lung (Gregoire, C. et 
al., 2007). NK cells are abundant in the liver sinusoids. NK cells have been shown to 
contribute to the pathogenesis of liver injury, fibrosis and regeneration (Sun, R. and Gao, 
B., 2004; Melhem, A. et al., 2006; Chen, Y. et al., 2007). NK cells are also implicated and 
in the development of NAFLD (Lamas, O. et al., 2004). In contrast, the cytotoxic activity of 
NK cells was observed to be significantly decreased in rats maintained on high fat diet 
when compared to control rats (Lamas, O. et al., 2004). Also, obese patients had 
significantly lower circulating NK (CD56+CD3-) cells (7.6% of all lymphocytes) when 
compared with lean healthy controls (16.6% of all lymphocytes) (O'Shea, D. et al., 2010). 
Another study reported an increase in hepatic NK cells in patients with NASH, but not in 
patients with NAFLD, while they are barely detectable in healthy controls (Kahraman, A. et 
al., 2010).  
Two different roles have been proposed for hepatic NK cells in the context of liver injury. 
First, NK cells exert an anti-fibrotic function by inducing cell cycle arrest and apoptosis in 
HSCs. Second, interferon-γ (IFN-γ) secreted by NK cells can induce the apoptosis of 
hepatocytes, which is one of the prominent feature of liver injury during the pathogenesis 
of NASH (Zhan, Y.T. and An, W., 2010). NK cell-regulating cytokines are involved in 
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NASH; for example, IL-18 as well as IL-12 are the most important KC-derived cytokines, 
which promote NK cell activation (Diehl, A.M., 2002). Another important cytokine in NK 
cell homeostasis and proliferation is IL-15, which will be discussing in later sections. 
NKT cells, co-express T-cell receptor (TCR) and NK cells markers (Balato, A. et al., 
2009).  In the fatty liver of leptin-deficient ob/ob mice, NKT cells were selectively reduced 
(Guebre-Xabier, M. et al., 2000). However, recent studies show that NKT cells accumulate 
in progressive fatty liver disease. For example hepatic CD3+CD56+ NKT cells increased 
during progression of NAFLD (Tajiri, K. et al., 2009). In patients with chronic liver disease, 
NKT cell accumulation coincides with the development of cirrhosis (Syn, W.K. et al., 
2010). However, the role of NKT cells in NAFLD is not clear. Recently Lynch, L. et al., 
showed that invariant NKT (iNKT) cells are decreased in mice maintained on HFD. The 
same group also reported a reduction in circulating iNKT population in obese patients 
(Lynch, L. et al., 2012). The iNKT cells (also known as classical, conventional or class-I 
NKT cells) express a restricted TCR repertoire composed of Va14–Ja18 and 
Vb8.2/Vb7/Vb2 chains in mice and homologous Va24–Ja18 and Vb11 chains in humans, 
and recognize glycolipid antigens in the context of the MHC-I-related protein CD1d 
(Bendelac, A. et al., 2007).  
The reported differences in the NKT cells infiltration in the fatty liver in several studies may 
be explained by the different fatty liver models used and the variety of markers that have 
been used to identify NKT cells. The role of the different subsets of NKT cells in fatty liver 
disease is not clear at present. Activation of NKT results in the upregulation of FAS ligand 
on their cell surface.  FAS ligand can interact with FAS that is expressed on hepatocytes 
inducing their apoptosis (Swain, M.G., 2008).  Based on this observation, it has been 
proposed that, therapies aimed at reducing the accumulation of NKT cells in the liver 
could be a therapeutic strategy to minimize liver damage in patients with NASH. 
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1.3.4. Mouse models of NAFLD 
The published models for fatty liver disease can be divided into two main groups: those 
caused by genetic mutations and those with an acquired phenotype produced by dietary 
modifications or pharmacological treatment. These models reproduce some of the 
features of human fatty liver disease, but not the complete phenotype (Anstee, Q.M. and 
Goldin, R.D., 2006). In the first group, leptin deficient mice (ob/ob) are is the most widely 
used mouse model. These mice became hyperphagic, inactive, obese and severely 
diabetic with marked hyperglycemia. Young ob/ob mice develop steatosis and become 
obese even on normal chow. Histological analysis of the liver tissues revealed fat 
deposition. Similar phenotype is also observed in mice and rats carrying a genetic 
invalidating mutations in the leptin receptor (db/db mouse and fa/fa rat) (Anstee, Q.M. and 
Goldin, R.D., 2006). 
In diet-induced models, the mice are maintained on diet that is high on carbohydrate (65% 
sucrose) or fat (high fat diet, HFD). By 8 weeks into these diets, mice develop hepatic 
steatosis with obesity, insulin resistance and macrovesicular steatosis (Anstee, Q.M. and 
Goldin, R.D., 2006). Mice on HFD gradually develop visceral adiposity, hyperglycemia, 
insulin and leptin resistance, as well as hepatic steatosis. On the other hand, mice fed 
with low fat diet do not gain weight, are euglycemic, have normal insulin and leptin levels, 
and do not develop hepatic steatosis (Collins, S. et al., 2004). As obesity is the main 
cause of fatty liver in the western countries, diet induced obesity (DIO) is a good model to 
study NAFLD. 
 
1.4. Cytokines that signal via the common γ-chain (γc; CD132) receptor 
Cytokines are a diverse group of soluble proteins, peptides, and glycoproteins that act as 
hormonal regulators of the immune system. They regulate proliferation, differentiation and 
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survival of immune cells. Type I cytokines include many interleukins, as well as some 
growth and hematopoietic factors. They have a common structure that contains four α-
helical bundles (Rochman, Y. et al., 2009). The cytokines that signal via the common γ-
chain (γc; also known as IL-2Rγ and CD132) constitute an important family cytokines. 
These include interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21 (Leonard, W.J., 2001). 
The γ-chain was first described as a part of IL-2 receptor, which is the prototypic member 
of this family (Takeshita, T. et al., 1992). In human patients the deficiency in the gene 
encoding this receptor subunit leads to X-linked severe combined immunodeficiency 
(XSCID). Phenotypic characterization of immune cells from those patients revealed a lack 
of T cells and NK cells (Noguchi, M. et al., 1993). Moreover, the immune defect in those 
patients is much more severe than in humans or mice lacking IL-2 only, suggesting that 
this receptor can be shared by others cytokines, as described later (Leonard, W.J., 2001). 
IL-2, also known as T cell growth factor, has an important role in the activation of NK and 
B cells (Kim, H.P. et al., 2006). It also promotes peripheral T cell tolerance by controlling 
the development of regulatory T cells (Treg), as well as regulating the proliferation and 
apoptosis of activated T cells (Lenardo, M.J., 1991; D'Souza, W.N. and Lefrancois, L., 
2003). The high-affinity receptor for IL-2 is composed of  three chains (IL-2Rα, IL-2Rβ and 
γc) (Takeshita, T. et al., 1992). 
IL-4 is a classical T helper 2 (Th2) cytokine that is required for the development and 
function of TH2 cells. In allergy and asthma, as well as in immunoglobulin class switching, 
IL-4 has been reported to play a critical role (Holgate, S.T. and Polosa, R., 2008). IL-7, 
another member of the IL-2 family of cytokines, is required during the early stages of T 
cell development in the thymus (Mazzucchelli, R. and Durum, S.K., 2007). It is also 
required for the survival of mature T and B cells. However, NK cell development and 
acquisition of effector functions is perfectly normal in the absence of IL-7 (Surh, C.D. and 
Sprent, J., 2008). It should be noted that IL-7Rα is used in combination with the Cytokine 
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Receptor-like factor 2 to form the thymic stromal lymphopoietin receptor (TSLPR). IL-7 is 
also required for the development of B cells in mice but it is not necessary for B cell 
development in humans (Rochman, Y. et al., 2009). 
IL-9 production was first associated with the Th2 phenotype, and many of the preliminary 
functions of IL-9 were tested in models of Th2-associated immunity (Gessner, A. et al., 
1993). IL-9 is produced by a subset of activated CD4+ T cells and it induces the activation 
of epithelial cells, B cells, eosinophils and mast cells (Hauber, H.P. et al., 2004). Other Th 
subsets also appear to have the potential to produce IL-9. Th17 cells, which are 
characterized by the secretion of IL-17A and IL-17F, may also secrete IL-9 in vitro and ex 
vivo (Elyaman, W. et al., 2009). IL-9R has two subunits: the α-chain (IL-9Rα) and the 
common γ-chain receptor (Renauld, J.C. et al., 1992), and is expressed on T cell lines 
and effector T cells but not naive T cells (Cosmi, L. et al., 2004). 
Interleukin-21 (IL-21), the most recently discovered IL-2 family member, is believed to be 
a key factor in the transition between innate and acquired immunity. IL-21 is secreted by 
activated NKT cells, CD4+, but not CD8+ T cells, CD19+ B cells, CD14+ monocytes and 
dendritic cells (Brandt, K. et al., 2003). IL-21 is preferentially expressed in Th2 cells in 
murine models, whereas in humans IL-21 mRNA was detected in Th1 cells and in 
follicular helper T cells (Pelletier, M. and Girard, D., 2007). A more detailed study showed 
that human IL-21 is mainly expressed by activated CD4+ central and effector memory T 
cells, some activated Th1-polarized cells, but not Th2-polarized cells (Onoda, T. et al., 
2007). IL-15 is essential for the development of NK cells the homeostasis of CD8+ T cells 
(Rochman, Y. et al., 2009). Given that this cytokine is the main subject of this thesis, it is 
discussed in detail in the following section. 
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1.5. Interleukin-15 (IL-15) 
1.5.1. Structure 
IL-15 is a 14–15kDa cytokine containing 114 amino acids and is located in human 
chromosome 4q31, and the central region of mouse chromosome 8 (Waldmann, T.A., 
2006). The genomic structure of human IL-15 contains 9 exons (7 coding exons), with a 
similar intron/exon structure (Anderson, D.M. et al., 1995a). The overall intron/exon 
structure of IL-15 is similar to that of the IL-2 gene and other 4 α-helix bundle cytokines. 
However, at the nucleotide or protein level, there is minimal homology between IL-2 and 
IL-15 (Fehniger, T.A. and Caligiuri, M.A., 2001). 
IL-15 precursor protein contains a long 48–amino acid leader peptide and a 114-AA 
mature protein (Nagarajan, S. et al.). Identification of human, simian, and murine IL-15 
indicated that this cytokine was conserved between species (97% identity between human 
and simian; 73% identity between human and murine) (Grabstein, K.H. et al., 1994). An 
alternative IL-15 precursor protein expresses a 21-AA short signal peptide (SSP) 
compared to the originally discovered IL-15 precursor with 48-AA long signal peptide 
(LSP). However, both IL-15 isoforms encode an identical mature IL-15 protein in human 
and mouse  (Fehniger, T.A. and Caligiuri, M.A., 2001). Both LSP–IL-15 and SSP–IL-15 
appear to have 2 to 3 log-fold less secretion than IL-2. Studies with IL-15–green 
fluorescent protein (GFP) fusion protein, show that LSP–IL-15 was targeted to the 
secretory pathway (ER/ Golgi apparatus), whereas SSP–IL-15 appeared to be restricted 
to the cytoplasm and nucleus (Gaggero, A. et al., 1999). SSP–IL-15 mRNA is expressed 
in the heart, thymus, appendix, and testis, whereas LSP–IL-15 is in skeletal muscle, 
placenta, heart, lung, liver, thymus, and kidney. The biologic significance of these different 
IL-15 isoforms is not clear (Gaggero, A. et al., 1999). 
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1.5.2. IL-15 receptor 
The structure of the IL-15/IL-15R quaternary complex bears similarity to that of the two 
other γc-containing cytokine-receptor complexes reported so far, IL-2 and IL-4 (Wang, X. 
et al., 2005; LaPorte, S.L. et al., 2008).  The IL-15 quaternary complex, containing its own 
α-receptor subunit and the shared signalling receptors IL-2Rβ (CD122) and γc, assembles 
in a way nearly identical to that of the IL-2 quaternary complex (Protein Data Bank 
accession code, 2B5I), with IL-2Rβ binding to site I on the cytokine and γc binding to site II 
(Ring, A.M. et al., 2012). The IL-2R/15Rβ receptor contain a 214 amino acid extracellular 
segment, a 25 amino acids transmembrane region (Balato, A. et al.), and a 286-amino 
acid cytoplasmic domain (Hatakeyama, M. et al., 1989). The human γc consists of a 233-
amino acid extracellular domain, a 28-amino acid TM domain, and an 86-amino acid 
cytoplasmic region (Takeshita, T. et al., 1992). IL-15Rα is structurally similar to IL-2Rα 
with a conserved extracellular protein-binding Sushi domain. IL-15Rα has a 173-amino 
acid extracellular domain, a single 21-amino acid TM region, and a 37 amino acid 
cytoplasmic domain (Takeshita, T. et al., 1992).  
The gene coding for IL-15Rα (Il15ra) is located on human chromosome 10 and contains 
seven exons. Alternative splicing leads to eight different isoforms of IL-15Rα (Dubois, S. 
et al., 1999). In humans there are three types of splicing events: (i) alternative usage of 
exon 7 or 7’; (ii) deletion of exon 3 encoding the linker region, and (iii) deletion of exon 2, 
which encodes the Sushi domain and thus cannot bind IL-15 (Dubois, S. et al., 1999).  IL-
15Rα alone is sufficient for high-affinity (Kd greater than or equal to 10-11 M) binding of IL-
15, but, like IL-2Rα, it plays no role in signal transduction. Thus, the signal transduction 
can happen only in the presence of the IL-2/15Rβ and γc, even if IL-15Rα binds IL-15 with 
high affinity. IL-15, like IL-2, may also bind and signal through the heterodimeric IL-
2/15Rβγc with intermediate affinity (Kd approximately 10-9 M) in the absence of IL-15Rα 
(Armitage, R.J. et al., 1995).  
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Transcript levels of full-length IL-15Rα are found in numerous tissues and cell lines (Steel, 
J.C. et al., 2010). In certain tissues such as brain, intestine, liver, peripheral blood 
mononuclear cells [PBMCs], the expression of all 8 IL-15Rα isoforms was observed; 
however, the relative expression of each isoform varied (Anguille, S. et al., 2009). IL-15Rα 
mediates proliferative and homing functions that are essential for the homeostasis of 
mature lymphocytes. Lodolce et al. (Lodolce, J.P. et al., 1998), show that Il15-/-, Il15ra-/-, 
Il2rb-/- and Il2rg-/- mice are deficient in NK, NKT, and TCRγδ intraepithelial lymphocytes 
(IELs). Thus, they proposed that all the 3 subunits of IL15R are required for IL-15-
mediated signals during the development of these cell types. The dependence of NKT 
lymphocytes and TCRγδ IELs on IL-15Rα appears to be intermediate between NK cells 
and CD4+ T lymphocytes, suggesting that other cytokines (e.g., IL-7) may partly 
compensate for IL-15 in the differentiation of NKT lymphocytes and TCRγδ IELs (Lodolce, 
J.P. et al., 1998). CD8 single positive (SP) thymocytes were reduced in IL-15RαKO mice 
indicating that intrathymic T cell differentiation of CD8 SP, but not CD4 SP thymocytes is 
dependent on  IL15Rα (Lodolce, J.P. et al., 1998).  
1.5.3. IL-15 signalling 
IL-15R signalling leads to activation of the Janus kinase (Sabatti, C. et al.) and Signal 
Transducer and Activator of Transcription (STAT) pathway. CD122 recruits JAK1, which 
leads to the phosphorylation of STAT3. The γc recruits and phosphorylates JAK3, which 
leads to the phosphorylation of STAT5. Once phosphorylated, STAT3 and STAT5 form 
homo- or hetero-dimers and translocate to the nucleus where they are responsible for the 
activation of certain genes (Johnston, J.A. et al., 1995). The IL-15 signalling pathway can 
also induce phosphorylation of Lck and spleen Tyr kinase (Syk) kinase (Ratthe, C. and 
Girard, D., 2004; Uhlin, M. et al., 2005).  
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1.5.4. Mechanisms mediating IL-15 responses 
As IL-15 was initially identified through its ability to mimic IL-2–induced T-cell proliferation, 
the biochemical and functional relationship between these two cytokines were examined 
in detail. IL-2 and IL-15 signalling starts when the cytokines bind IL-2Rα or IL-15Rα, 
respectively, and are presented to IL-2Rβ and γc.  IL-15 can also be presented in trans, by 
cells expressing IL-15Rα, to IL-15-responsive cells expressing IL-2Rβ and γc (Ring, A.M. 
et al., 2012). In 2001, it was reported that IL-15 response in T cells did not required IL-
15Rα expression in the lymphocytes, but was absolutely dependent on the IL-15Rα 
expression by the non-hematopoietic cells (Lodolce, J.P. et al., 2001). Given that IL-15 
was previously shown to have direct effect on T cells, other investigations were performed 
in order to elucidate the role of IL-15Rα expression in others cells. In 2002, Dubois et al. 
(Dubois, S. et al., 2002) proposed the theory of trans-presentation based on the effect of 
IL-15R component on responding T cells and in monocytic cell lines. In this study, they 
showed that the effect of IL-15 on T cells was longer than that of IL-2 since IL-15R 
allowed for the continued presence of IL-15 on the cell surface of monocytes. Moreover, 
IL-15 and its α-receptor associate in the endoplasmic reticulum (ER) (Dubois, S. et al., 
2002). The finding that IL-15R shuttles IL-15 to the cell surface suggest that IL-15 is not 
secreted, providing an explanation for the inability to detect IL-15 in biological fluids. 
Overall, trans-presentation was proposed as a mechanism to explain how the expression 
of IL-15Rα by neighbouring cells was crucial for IL-15 to signal through the βγc (Dubois, S. 
et al., 2002). 
The theory of IL-15 trans-presentation was postulated based on in vitro experiments, but 
subsequent in vivo results provided additional evidence. The generation of antigen-
specific memory CD8+ T cells and their homeostatic proliferation in vivo was independent 
of IL-15Rα expression in T cells, but the response required IL-15Rα expression by the 
host cells (Schluns, K.S. et al., 2004a). Moreover, similar results were found in NK cells 
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development and homeostasis. Using specific combinations of cell transfers and bone 
marrow (BM) chimeras, Ma, A. et al., proved that NK cells require IL-15R expression by 
the cells in their environment but did not need self-expression (Koka, R. et al., 2004).  
IL-15 trans-presentation is not the result of surface-capture effect mediated by IL-15 
binding to IL-15Rα in the same cell, as is the case for IL-2. Nevertheless, trans-
presentation has proven to be a major mechanism of IL-15 action in vivo, which suggests 
that IL-15Rα may have other IL-15-sensitizing functions in addition to surface capture. For 
example, Aaron et al., suggested that IL-15Rα might stabilize a conformation of IL-15 that 
is more able to bind IL-2Rβ, akin to the effect of IL-2Rα for IL-2 (Ring, A.M. et al., 2012). 
IL-15Rα binding increased the affinity of IL-15 for IL-2Rβ approximately 150-fold (Ring, 
A.M. et al., 2012). IL-15Rα is widely expressed in the tissues, IL-15 is believed to exist in 
the body mainly in a complex with IL-15Rα and is therefore primed for trans-presentation 
to cells that express IL-2Rβ and γc (Stonier, S.W. and Schluns, K.S., 2010). The 
cytoplasmic domain of IL-15Rα, like that of IL-2Rα, appears to be dispensable for 
signalling. Indeed, it has been reported that high concentration of IL-15 can bind and 
transduce a signal in cells expressing only the IL-2Rβ and γ chains, as can IL-2 
(Anderson, D.M. et al., 1995b).  
Other groups have proposed alternative mechanisms for IL-15 responses and delivery. 
Following Vesicular stomatitis virus (VSV) infection, it was found that CD8+ T cell 
expansion was partially defective in the absence of IL-15 but was not defective in the 
absence of IL-15Rα (Schluns, K.S. et al., 2002). This suggested that in an inflammatory 
context, an abundance of sIL-15 (define soluble or surface, as sIL-15 can mean both) may 
be available to act through the βγc complex and bypass IL-15Rα trans-presentation. In this 
scenario, IL-15Rα is completely dispensable. As described above, numerous studies 
postulate that the expression of IL-15Rα is not required on IL-15-dependent cells (i.e. 
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CD8+ T cells, NK cells, and IELs).  However, lymphocytes express some of the highest 
levels of IL-15Rα, the significance of which is not known (Schluns, K.S. et al., 2004b). 
Crystal structure of IL-15Rα revealed a threonine/proline-rich region between the trans-
membrane and the IL-15 binding domain, that confers flexibility. This suggests that IL-
15Rα can also present IL-15 to βγc in the same cell, in a process called as cis-
presentation (Olsen, S.K. et al., 2007). The physiological relevance of this process has not 
been yet elucidated. Transfection experiments with IL-15Rα in naïve CD8+ T cells showed 
that the response to IL-15 is enhanced in transfected cells versus non-transfected 
counterparts (Rowley, J. et al., 2009). Another group reported that IL-15Rα knock-in in T 
cells had slightly increased levels of homeostatic proliferation (Wu, Z. et al., 2008). Taken 
together, these observations reveal that cis-presentation can also mediate IL-15-induced 
responses. In the Fig 1.1 we summarise the main mechanisms for IL-15 delivery to the 
responsive cells. 
 
Figure 1.1: Principals mechanism for IL-15 delivery. A)  Trans-presentation: IL-15Rα 
and IL-15 are synthetized in the same cell and transported to the cell surface where the 
cell surface complex can stimulate neighboring cells through the IL-15R βγc. B) Cis-
presentation: IL-15 is presented by IL-15Rα on the same cell; these mechanisms may 
utilize IL-15 derived from autocrine or paracrine sources (Stonier, S.W. and Schluns, K.S., 
2010).    
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1.5.5. Function of IL-15 in T cells   
IL-15 induces proliferation of naïve CD8+ and memory CD4+ and CD8+ T cells (Kanegane, 
H. and Tosato, G., 1996; Stoklasek, T.A. et al., 2006). In the presence of IL-15, CD4+ and 
CD8+ T cells resist the regulatory effects of Tregs (Ben Ahmed, M. et al., 2009). IL-15 also 
has demonstrated chemotactic activity towards CD4+ and CD8+ T cells (Wilkinson, P.C. 
and Liew, F.Y., 1995).  
The anti-apoptotic effects of IL-15 in lymphocytes are mediated by the upregulation of 
anti-apoptotic proteins of the Bcl-2 family. Stimulation with IL-15 increases the levels of 
anti-apoptotic proteins BCL-2, BCL-xL, MCL-1 (Lodolce, J.P. et al., 1998; Becker, T.C. et 
al., 2002) and downregulates pro-apoptotic proteins BAX, BID, BIM, NOXA and PUMA 
(Van Belle, T. and Grooten, J., 2005; Huntington, N.D. et al., 2007). IL-15 can also 
prevent apoptosis by activating NF-kB (Hoontrakoon, R. et al., 2002), and inhibiting 
caspase-3 and -8 (Bouchard, A. et al., 2004). Long-term survival, proliferation and 
renewal of memory CD8+ T cells by IL-15 are mediated by the upregulation of Bcl-2 
(Lodolce, J.P. et al., 1998; Becker, T.C. et al., 2002). As a result, Il15-/- and Il15ra-/- mice 
lack memory CD8+ T cells (Lodolce, J.P. et al., 1998; Kennedy, M.K. et al., 2000). 
 
1.5.6. IL-15 in NK cell biology 
Natural killer cells (also known as NK cells, K cells, and killer cells) are a type of 
lymphocytes that play a major role in elimination of both tumours and viral infected cells. 
Their functions do not require priming. While the earliest stages of NK cells development 
is confined to the BM, the later stages of development is a continuous process that occurs 
in both the BM and peripheral tissues, such as the spleen and liver. In the BM, the 
common lymphoid progenitor differentiates into NK precursors (NKp), which express IL-
15Rβ (Schluns, K.S. et al., 2004a). In mice, transition from NKp to immature NK cells is 
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marked by the expression of NKG2D, NK1.1 and the CD94/NKG2 heterodimeric complex. 
This is followed by the increased expression of both activating and inhibitory Ly49 
receptors (Ly49R) (Kim, S. et al., 2002). Maturation of NK cells is characterized by 
increased killing capacity and pro-inflammatory cytokine secretion, as well as the 
expression of CD49b (DX5) (Yajima, T. et al., 2001). These functional attributes become 
enhanced with the upregulation of CD11b and CD43, which identifies the second stage of 
maturation (Kim, S. et al., 2002). There are many transcription factors involved in NK cell 
differentiation and functional maturation, such as Id2, Id3, Ikaros, Runx3, E4bp4, Gata-3, 
T-bet and Eomesodermin (Boggs, S.S. et al., 1998; Gordon, S.M. et al., 2012).  
IL-15 is indispensable for NK cell development. The absence of IL15 or its receptor 
components results in a decrease of this cell population (DiSanto, J.P. et al., 1995; 
Lodolce, J.P. et al., 1998; Kennedy, M.K. et al., 2000). IL-15-mediated upregulation of the 
expression of anti-apoptotic molecules Bcl-2 and Mcl-1 and the downregulation of pro-
apoptotic molecules Bim and Noxa also mediate the survival of NK cells (Huntington, N.D. 
et al., 2007; Nakazato, K. et al., 2007). Activation of NK cells is also dependent on IL-15. 
Accumulating evidence suggests that trans-presentation of IL-15 is essential for the 
activation of NK cells. In lymphopenic recipients, adoptively transferred IL-15Rα-deficient 
NK cells can survive, but this response requires IL-15Rα expression by the recipients 
(Koka, R. et al., 2003). Interestingly, the lack of IL-15Rα in non-hematopoietic cells does 
not affect NK cell numbers. However, trans-presentation of IL-15 by hematopoietic cells is 
more efficient than that by non-hematopoietic cells.  Limiting IL-15Rα expression to 
hematopoietic cells alone is sufficient to generate normal NK cell numbers in the BM, 
while their numbers are only slightly reduced in the periphery (Schluns, K.S. et al., 2004b). 
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1.5.7. The role of IL-15 in iNKT cells 
iNKT cells are an NKT cell subset that expresses an invariant TCR that recognizes 
galactoceramide and do not require antigen priming for activation. Development of iNKT 
cells in the thymus and their homeostasis in the periphery are dependent on IL-15 
(Kennedy, M.K. et al., 2000; Matsuda, J.L. et al., 2002). Il15ra-/- as well as Il15-/- mice 
present similar defects in iNKT cells (Matsuda, J.L. et al., 2002; Matsuda, J.L. et al., 
2006). In the thymus, IL-15 enhances the survival of developing iNKT cells (Castillo, E.F. 
et al., 2009; Chang, C.L. et al., 2011; Gordy, L.E. et al., 2011). Moreover, it has been 
shown that IL-15 upregulates anti-apoptotic factors, such as Bcl-2, BclxL and Mcl-1 and 
downregulates proapoptotic factors like Bim (Huntington, N.D. et al., 2007). Conversely, in 
the periphery, IL-15 regulates both proliferation and survival of iNKT cells. IFN-γ 
production by iNKT cells following a-galactosylceramide stimulation is deficient in Il15ra-/- 
mice suggesting that IL-15 signalling also regulates their activation (Chang, C.L. et al., 
2011; Gordy, L.E. et al., 2011). Unlike NK cells, which require IL-15Rα expression on 
hematopoietic cells, IL-15Ra expressed on non-hematopoietic cells is sufficient for thymic 
iNKT development (Castillo, E.F. et al., 2010; Chang, C.L. et al., 2011). 
In the thymus, selective expression of IL-15Rα in dendritic cells (DCs) had no impact on 
iNKT development whereas IL-15 trans-presentation by medullary thymic epithelial cells 
(mTECs) seems to play a major role in the development and functional maturation of iNKT 
cells (Castillo, E.F. et al., 2010). In the periphery, studies using BM chimeras and 
transgenic models suggest that IL-15Rα expression is equally important in both 
hematopoietic and non-hematopoietic cells (Castillo, E.F. et al., 2010). IL-15Rα 
expression only by hematopoietic cells or DCs lead to a defective thymic iNKT 
development while differentiation and expansion of hepatic iNKT cells is relative normal, 
demonstrating the existence of IL-15-mediated extrathymic iNKT cell development 
(Castillo, E.F. et al., 2010). 
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In the liver, IL-15 is produced by liver resident DCs, macrophages (KCs) and hepatic 
stellate cells (non-hematopoietic origin). DC-mediated IL-15 trans-presentation generates 
functionally mature iNKT cells (Castillo, E.F. et al., 2010). As the role of KCs and HSCs 
cells in IL-15 trans-presentation is less clear, future studies using different IL-15Rα-
conditional KO mice are needed to elucidate their role. Overall these studies suggest that 
IL-15 trans-presentation by the tissue microenvironment is absolutely required for the 
maintenance of iNKT cells in peripheral tissues. 
 
1.5.8. IL-15 functions in non-immune cells 
Mesenchymal stem cells, osteoblasts, adipocytes, endothelial cells and myoblasts 
express high amounts of IL-15 mRNA (Nilsen, E.M. et al., 1998; Satoh, J. et al., 1998; 
Silva, W.A., Jr. et al., 2003), suggesting that IL-15 could have some effects on these non-
immune cells. For example, fibroblasts are the main source of increased levels of IL-15 in 
the synovium of rheumatoid arthritis (RA) patients (Miranda-Carus, M.E. et al., 2004). 
Moreover, apoptosis of synovial fibroblasts as well as TNFα-induced apoptosis in mouse 
L929 fibroblasts is inhibited by IL-15 (Yang, L. et al., 2002; Budagian, V. et al., 2005). IL-
15 stimulates the formation of osteoclast-like cells in rat bone-marrow cultures in vitro. 
Also, stimulation with IL-15 induces the expression of calcitonin receptor mRNA in 
preosteoclasts (Ogata, Y. et al., 1999). In RA patients IL-15 aggravates bone destruction 
by stimulating excessive bone resorption by osteoclasts (Ogata, Y. et al., 1999; Miranda-
Carus, M.E. et al., 2006). 
Epithelial cells lines such as human keratinocytes and immortalized HaCaT keratinocytes 
express both IL-15 and IL-15Rα (Ruckert, R. et al., 2000). IL-15 inhibits apoptosis in 
keratinocytes (Ruckert, R. et al., 2000; Yano, S. et al., 2003). Additionally, IL-15 induces 
epithelial cells proliferation through the activation of ERK1/2, PI3K and Akt pathways 
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(Yano, S. et al., 2003). Tubular epithelial cells (TECs) are a rich source of IL-15 that 
stimulates intratubular CD8+ T cells (Robertson, H. and Kirby, J.A., 2003). Also IL-15 is an 
autocrine survival factor for TECs, protecting them from apoptosis and inhibiting 
manifestation of nephrotoxic serum-induced glomerulonephritis (Shinozaki, M. et al., 
2002). 
Extravasation of activated T cells is stimulated by IL-15 since this cytokine induces 
hyaluronan expression by endothelial cells. Interaction between cell-surface glycoprotein, 
CD44, and hyaluronan is important for T cells adhesion and recruitment to the blood 
vessel wall (Estess, P. et al., 1999). Endothelial cell-derived IL-15 induces 
transendothelial migration of T cells by activating the binding capacity of LFA-1 integrin, 
and increases T-cell motility (Oppenheimer-Marks, N. et al., 1998). 
Muscles express high levels of IL-15 mRNA (Grabstein, K.H. et al., 1994). IL-15 has 
anabolic effects in the muscle in vitro, as described for insulin growth factor-1 (IGF-1) 
(Quinn, L.S. et al., 1995). Overexpression of IL-15 induces skeletal muscle hypertrophy in 
vitro (Quinn, L.S. et al., 2002). The general reduction of proteolysis induced by IL-15 could 
be the main mechanism involved in its anabolic effects (Busquets, S. et al., 2005). IL-15 
has been also described as a myokine (cytokines which are secreted by muscle cells) with 
effects on adipose tissue. Muscle-to-fat endocrine axis is responsible for fat body 
composition and insulin sensitivity (Carbo, N. et al., 2001; Quinn, L.S. et al., 2005). 
Interesting, IL-15 sensitivity differ in different adipocyte subpopulations and there are also 
species- and developmental stage- dependent differences. For example in 3T3-L1 
preadipocytes, IL-15 inhibits lipid deposition while it has no effect on lipid deposition in 
fully differentiated 3T3-L1 cells (Quinn, L.S. et al., 2005).  
The wide range of expression of IL-15 and its receptor also occurs in the central nervous 
system. IL-15 mRNA is detected in microglia, astrocytes and neuronal cell lines. Low 
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doses of IL-15 support microglial cell growth, attenuats their nitric oxide production and 
induce JAK1 phosphorylation (Hanisch, U.K. et al., 1997; Kurowska, M. et al., 2002). 
1.5.9. Functional dichotomy between IL-2 and IL-15 
IL-15 and IL-2 have similar biologic properties in vitro, consistent with their shared 
receptor signalling components (IL-2/15Rβγc). Like IL-2, IL-15 stimulates lymphocyte 
activation and proliferation in vitro (Bamford, R.N. et al., 1994; Armitage, R.J. et al., 1995). 
This stimulation occurs via both promotion of cell proliferation and protection against 
apoptosis. Despite the apparent similarities, in vivo experiments with IL-2 and IL-2RαKO 
mice indicate that IL-2R and IL-15R are not redundant proteins (Lodolce, J.P. et al., 
1998). IL-2 and IL-2Rα mice suffer severe lymphadenopathy and autoimmunity 
suggesting the critical role of IL-2 in the regulation of immune response (Sadlack, B. et al., 
1993). IL-2R functions cannot be compensated by IL-15R or by other cytokines of the Ɣc 
receptors family. Thus, IL-15R likely performs distinct immune functions from IL-2R in 
vivo. Accordingly, IL15Rα-deficient mice show lymphopenia and innate immune deficiency 
(Lodolce, J.P. et al., 1998). Moreover, the cellular distribution of the distinct IL-15Rα and 
IL-2Rα chains might also contribute to the temporal and spatial distinction between the IL-
2 and IL-15 induced activation of the via βγc-dependent signalling pathways (Fehniger, 
T.A. and Caligiuri, M.A., 2001). 
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1.6. The thesis premises 
Obesity is considered as a major problem in this decade. This condition is frequently 
associated with the increased prevalence of fatty liver disease. Liver diseases can evolve 
from benign non-alcoholic fatty changes to NASH, and in the long-run to hepatocellular 
carcinoma (Haslam, D.W. and James, W.P., 2005). Chronic low-grade inflammation is a 
common feature of obesity and NAFLD. Under obese conditions, inflammatory cells 
infiltrate the adipose tissues and liver. In addition to activation of resident immune cells, 
inflammatory cells are also recruited from the circulation. In the normal liver, immune cells 
are mainly represented by NK, NKT and CD8+ T cells, whereas in fatty liver disease there 
is an increase in the infiltration and activation of these cells, in addition to the activation of 
liver-specific macrophages (KCs) and Th1 cells (Li, Z. and Diehl, A.M., 2003; Zhan, Y.T. 
and An, W., 2010). NASH and NAFLD are extensively related to an imbalance in the 
cytokines in the liver towards pro-inflammatory microenvironment. KCs, stellate cells and 
other cells can produce the inflammatory cytokines TNF-α, IL-12 and IL-6 upon activation 
(Li, Z. et al., 2003). IL-15 is another pro-inflammatory cytokine, which is indispensable for 
the development and homeostasis of CD8+ T cells, NK, NKT and iNKT cells (Kennedy, 
M.K. et al., 2000). As these cells are implicated in perpetuation of inflammation in obesity, 
and the influence of IL-15 on these cells in the liver under conditions of obesity is unclear, 
I have addressed these issues using IL-15 knockout mice under conditions of diet-induced 
obesity. 
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1.7. Hypothesis 
Based on the above premises, we hypothesize that IL-15 signalling in liver cells 
promotes the development of NAFLD by inducing hepatic inflammation. 
1.8 Objectives 
The specific aims of my research project are: 
1. To evaluate the role of IL-15 in the development of NAFLD 
a. Characterize the induction of NAFLD by HFD in WT and Il15-/- mice using 
macroscopic and microscopic analysis of the liver and serum lipids levels. 
b. Evaluate the expression of genes involved in metabolism in the livers of 
WT and Il15-/- after HFD. 
c. Elucidate the role of IL-15 in the metabolic behavior of primary murine 
hepatocytes  
2. To characterize HFD-induced inflammation in the liver 
a. Evaluate intrahepatic lymphocytes (NK, NKT, iNKT, T cells) and 
macrophages infiltration after HFD. 
b. Evaluate inflammation related genes expression in liver samples and 
primary hepatocytes. 
3. To define the role of IL-15 and IL-15Rα in the maintenance of NK and NKT 
subsets in the liver 
a. Characterize IHLs in WT, Il15-/- and Il15ra-/-  
b. Characterize IHLs in macrophages and hepatocyte tissue-specific 
Il15ra deficient mice  
Materials and Methods 
 
29 
 
2. MATERIALS and METHODS 
2.1. Mice 
All the mice used were in C57BL/6 background. Mice were maintained in filter-topped 
cages in a specific pathogen-free facility and fed with standard chow diet and water unless 
specified otherwise. All experiments were carried out with the approval of the institutional 
ethics committee.  
Wild type (WT) C57BL/6 mice were from the Jackson laboratory. Il15-/- mice have been 
already described (Ramanathan, S. et al., 2006). Il15ra-/- mice were purchased from 
Charles River and bred into C57BL/6 background for more than ten generations. 
Conditional Il15ra-floxed mice, with loxP sites were inserted in the first and third intron of 
Il15ra locus (Il15rafl/fl), (Mortier, E. et al., 2009) were a generous gift from Dr. Averil Ma, 
University of California at San Francisco, USA. Tissue specific deletion of Il15ra was 
achieved by crossing these mice with Alb-Cre or LysM-Cre transgenic mice (purchased 
from the Jackson Laboratory) to ablate the IL-15Rα gene specifically in hepatocytes 
(Il15rafl/fl Alb-Cre+) or macrophages (Il15rafl/fl LysM-Cre+) respectively. 
 
2.1.1 Induction of NAFLD in mice 
To induce hepatic steatosis, 8-weeks old WT, Il15-/- and Il15ra-/- mice, were maintained on 
high fat diet (HFD) (Product Data-D12492: 20%kcal protein, 20% carbohydrate and 60% 
fat). Mice fed with normal control diet (NCD) were used as controls. These experiments 
were performed in male mice. Female mice were not used as they show hormone-
mediated resistance to obesity induction (Hong, J. et al., 2009). Mice were maintained on 
NCD or HFD for 16 weeks before sacrifice. The body weight and the weight of liver and 
adipose tissues were measured at sacrifice.  Aliquots of tissues were stored in formalin for 
Materials and Methods 
 
30 
 
histology, in OCT (optimal cutting temperature gel-like medium consisting of polyethylene 
glycol and polyvinyl alcohol) for immunohistochemistry and snap frozen in liquid nitrogen 
for RNA and protein extractions. 
2.2. Isolation of intrahepatic lymophocytes (IHL) 
Mice were sacrificed and the livers were collected and rinsed with Krebs-Ringer-Buffer 
(KRB, 154 mM NaCl, 5.6 mM KCl, 5.5 mM Glucose, 20.1 mM HEPES, 25 mM NaHCO₃, 
pH 7.4). The liver tissues were digested in pre-warmed KRB supplemented with 2mM 
CaCl₂, 2mM MgCl₂, 300 CDU (Collagenase digestion unit)/ mL Collagenase IV 
(Worthington) and 150 U/mL DNase I (Sigma) using gentleMACS Dissociator (Miltenyi 
Biotec) according to the instructions of the manufacturer. Next, the homogenized liver 
samples were gently agitated on a rocking shaker for 30 minutes at room temperature. 
The tubes were left on a stand for 1 minute to precipitate undigested liver tissue and the 
supernatants were passed through 40µm cell strainers. Cells were resuspended in 25 ml 
of cold PEB buffer (0.5% Bovine serum albumin and 2mM EDTA in Phosphate buffered 
saline (PBS)) and centrifuged at 50×g for 5 minutes at 4 °C to eliminate contaminating 
hepatocytes. The supernatant was centrifuged at 300×g for 10 minutes at 4 °C to collect 
the lymphocytes. Cells were resuspended in a buffered solution of ammonium chloride-
potassium (ACK) (155 mM NH4Cl, 1mM KHCO3, 0.5 mM EDTA, pH 7.2) to lyse the red 
blood cells. The remaining cells were washed twice with PEB buffer and used to prepare 
the single cell suspension for FACS analysis. 
2.3. Isolation of splenocytes 
Single cell suspensions were prepared by teasing the spleens in PBS containing 2% 
foetal calf serum (FCS). The suspension was centrifuged at 300×g and the supernatant 
was discarded. Red blood cells were lysed by resuspending in ACK solution for one 
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minute. After washing with PBS-FCS 2%, the cells were counted and resuspended in 
PBS-FCS 2%, for FACS staining and analyses. 
2.4. FACS analyses 
IHL and splenocytes were stained with the corresponding antibodies (Armitage, R.J. et al.) 
at RT, 15 minutes and washed with PBS before analyses. Abs against mouse CD3, 
CD8α, CD4, CD44, CD62L, NK1.1 conjugated to PE-Cy5.5, PE, APC-Cy7, FITC and APC 
were purchased from BD Biosciences (San Jose, CA), Biolegend (San Diego, CA) or 
eBioscience (San Diego, CA). Mouse CD1d tetramer pre-loaded with α-GalCeramide 
(CD1d*) conjugated to PE was a kind gift of Professor Yi-Guang Chen, Department of 
Pediatrics, Max McGee National Research Center for Juvenile Diabetes, Medical College 
of Wisconsin, Milwaukee, USA. Data was acquired on FACS Canto flow cytometer (BD 
Biosciences San Diego, CA) and was analyzed using FlowJo software from TreeStar Inc 
(Ashland, OR). 
2.5. Isolation of primary hepatocytes  
Primary hepatocytes isolation was carried out in 6-8 weeks-old mice as described 
previously (Gui, Y. et al., 2011). Intra-peritoneal injection of a mixture of Ketaset® (100 
mg/kg, Wyeth, Guelph, Canada) and Xylazine (10 mg/kg) was used as anesthetic. Liver 
perfusion was performed through the portal vein, the thoracic segment of the inferior vena 
cava was clamped and the abdominal segment was cut, allowing a closed circulation in 
the liver. The liver was first perfused with 25 ml Ca2+/Mg2+-free Hank’s buffered salt 
solution (HBSS) containing 0.5 mM EGTA, kept warm in 37˚ water bath, at the rate of 7 
ml/min. After, the collagen digestion was made with 25 ml of collagenase type IV 
(100U/ml, Worthington, Lakewood, NJ, USA) in HBSS supplemented with CaCl2 (1.8 mM) 
via the same route. After slicing the liver, hepatocytes were sedimented twice by 
centrifugation at 50 g at 4˚C to eliminate the non-parenchymal cells. Viability was 
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assessed by trypan blue exclusion and 0.5x106 hepatocytes in DMEM-F12 (Dulbecco’s 
Modified Eagle Medium: Nutrient Mixture F-12) (GibcoBRL, Burlington, ON, Canada) with 
10% FCS were seeded in collagen I (Sigma)-coated 35 mm culture dishes.  
2.6. Stimulation of hepatocytes 
Lyophilized recombinant human IL-15 (Peprotech) was reconstituted according to the 
manufacturer’s instructions and stored at -80˚C until used. Primary hepatocytes were 
starved overnight (ON) in DMEM-F12 with 0.1% FCS and stimulated with hIL-15 (20ng/ml) 
for 2 hours. Subsequently, the cells were washed twice and RNA extraction was 
performed.  
2.7. Assessment of mitochondrial respiration in hepatocytes 
Primary hepatocytes from WT and Il15-/- mice were isolated as described above and 
seeded in a 96 wells plate. Sensor cartridges were pre-incubated ON in XF96 calibrating 
solution in a non-CO2 incubator at 37ºC and XF96 Analyzer temperature was kept at 37ºC 
during the assay. Hepatocytes were kept in culture for 4 days until they acquired the 
appropriate morphology and reached approximately 90% confluence. On the day of the 
assay, cells were washed 3 times with XF Assay media (non-buffered media to accurately 
measure proton production rate and extra cellular acidification rate) and incubated in 150 
μl of the same medium in a non-CO2 incubator at 37ºC for 20 minutes before 
measurement the extracellular flux analyzer (XF96 Analyzer). The sensor cartridge was 
loaded with 15μl of pre-warmed respiratory chain inhibitors (diluted in XF Assay media) at 
pH 7.4 into appropriate ports. Then, the XF96 Analyzer software was run using the 
optimized protocol. While the protocol is running, the inhibitors are injected in sequence 
automatically, in order to evaluate the basal respiration, the maximum respiratory capacity 
and non-mitochondrial respiration in the cells. For example, oligomycin inhibits ATP 
synthase and consequently the oxygen consumption rate decreases to minimal level. The 
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second inhibitor is Carbonyl cyanide p-[trifluoromethoxy]-phenyl-hydrazone (FCCP), a 
chemical uncoupler of electron transport and oxidative phosphorylation, which boost the 
cells to their maximal respiratory capacity. In the end, rotenone and Antimycin A, 
respiratory complex inhibitors, are injected to the wells to decrease mitochondrial 
respiration to minimum values. Data was processed using the same software. The graphs 
represent the maximal respiratory capacity (MRC), calculated as the difference between 
the maximal respiration and the basal respiration. The Fig. 2.1 shows an XF Cell Mito 
Stress Test Profile. All the reagents and equipment used in this assay were from 
Seahorse Biosciences.  
 
 
Figure 2.1: XF Cell Mito Stress Test Profile. The fundamental parameters of 
mitochondrial function: basal respiration, ATP turnover, proton leak, and maximal 
respiration, or spare respiratory capacity. 
 
2.7.1 Fatty acids oxidation test 
To determine how IL-15 deficiency changes the capacity of hepatocytes to oxidize FAs, 
we used the XF Palmitate-Bovine serum albumin (BSA) Fatty Acids Oxidation (FAO) 
substrate according to company’s protocol (Palmitate-BSA FAO Substrate, Part #102720-
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100). Palmitate-BSA FAO integrates the XF Cell Mito Stress Test with the BSA Control 
and XF Palmitate reagent. Primary hepatocytes were isolated as described in Section 3.5 
and seeded in a 96 well plate. The day previous to the assay, the growth medium was 
exchanged for substrate-limited medium (DMEM, 0.5 mM Glucose, 1.0 mM GlutaMAXTM 
(life technologies), 0.5 mM carnitine and 1% FCS) and incubated ON. Next, cells were 
kept in FAO medium (Krebs-Henseleit Buffer (KHB) with 2.5 mM glucose, 0.5 mM 
carnitine and 5 mM HEPES) for 45 min and BSA control or Palmitate-BSA substrate was 
added. XF Cell Mito Stress Test analysis was performed following the protocol described 
in the previous section. 
2.8. Tissues processing for histology 
Mice were sacrificed and the tissues were sectioned and fixed in a 10% formalin solution.  
Fixative volume was approximately 20 times that of tissue on a weight per volume. The 
tissues were fixed for a minimum of 48 hours at room temperature and then kept at 4˚C. 
For paraffin infiltration the tissues were dehydrated through a series of graded ethanol 
baths to displace the water, and then infiltrated with paraffin. The infiltrated tissues were 
then embedded into paraffin blocks. Tissues were sectioned into 5 µm thick sections. 
Some tissue sections were kept frozen for immunohistochemistry or lipids staining. To 
preserve tissue morphology and retain the antigenicity of the target molecules, the tissues 
were fixed in paraformaldehyde (PFA)/PBS 4%, 5 min and kept ON at 4°C in 4% 
sucrose/PBS solution. The sucrose solution was changed daily to increase sucrose 
percentage up to 30%. Tissues were mounted in OCT embedding compound and frozen 
at -80°C. Tissue sections (7 µm) were cut using a cryostat and conserved at -20°C until 
use. 
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2.9. Histology and lipids detection 
Liver sections were de-paraffinized and rehydrated in serial dilutions of ethanol and water 
before staining. Slides were stained with Harris’s hematoxylin solution for 5 min, then 
washed in tap water and fixed in acid-water solution (1% acetic acid) followed by rinsing in 
saturated aqueous lithium carbonate. The slides were washed and stained with Eosin for 
1 minute and then washed in 50% ethanol before being dehydrated in increasing 
percentages of ethanol solutions and xylene. Subsequently the samples were 
coverslipped using Permount™ Mounting Medium (SP15-500, Fisher Scientific). 
Lipid staining was carried out using Sudan Black, a basic dye that combine with acidic 
groups in lipids compound, including phospholipids. Frozen sections were fixed with 10% 
formalin and immersed in 100% propylene glycol, two changes, 5 minutes each. Fat 
staining was made by 7 min incubation in Sudan Black (7% m: v in Propylene glycol) 
followed by two washes in Propylene glycol. The slides were washed in water and 
mounted with aqueous mounting media (VectaMount™ from Vector Labs). Images were 
taken using automatic tissue slide scanning (NanoZoomer Digital Pathology (NDP) 
system from Hamamatsu Photonics). 
2.10. Immunofluorescence microscopy 
Fresh liver tissue samples from WT mice in NCD or HFD were examined for macrophages 
infiltration. Slices were fixed in cold acetone 10 min and washed three times in PBS and 
blocked with 2% BSA in PBS for 45 minutes at 37˚C. Endogenous avidin and biotin were 
blocked using Avidin/Biotin Blocking kit (Invitrogen). All the steps were intervened with 
three times PBS-0.5% TWEEN®20(PBS/Tw) wash and were carried out at room 
temperature. Tissues were incubated ON at 4˚C with primary anti-CD68 biotinylated 
antibody (MCA 1957B, Serotec), washed in PBS/Tw and then incubated with streptavidin 
coupled to Alexa-488 Fluor and the nuclear stain DAPI for 1 hour at 4˚C. Indirect 
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immunofluorescence was examined without counterstain using an Axioskop 2 phase-
contrast/epifluorescence microscope (Carl Zeiss, Inc., Thornwood, NY, USA) equipped 
with a band pass filters for fluorescence of DAPI (excitation D360/40; emission D460/50) 
and FITC (excitation D480/30; emission. D535/40) (Chroma Technology Corp.). 
Photomicrographs of 1392 x 1040 pixels were captured using 40x objective and Retiga 
SRV cooled color digital camera (Qimaging, Burnaby, BC, Canada). 
2.11. RNA isolation  
Liver samples were snap frozen and kept at -80˚C until use. Liver samples were 
homogenized in TRIzol® (Life Technologies) using mixer mill MM 400 (Retsch, Hann, 
Germany). The cultured hepatocytes were directly lysed in TRIzol®. Chloroform was 
added for 10 min to homogenized samples which were then centrifuged to separate the 
phases. Subsequently, the aqueous phase was collected and isopropanol was added to 
precipitate the RNA. This step was followed by washing the RNA pellet in 75% ethanol 
and re-suspension in RNAse-free water. RNA purity was evaluated by measuring the 
260/280 nm and 260/230 nm absorption ratios and RNA quality was confirmed by running 
1 µg RNA on the denaturing formaldehyde-agarose gel. 
2.12. Quantitative PCR 
The first strand was synthesized from 1 µg total RNA using Quantitect® (Qiagen, 
Mississauga). The selected primers were examined for the efficiency and melting curve. 
Primer sequences are shown in table 2.1. Gene expression was evaluated with MyQi5® 
cycler (Bio-Rad) using SYBR Green Supermix (Bio-Rad). Fold induction was calculated 
based on the ribosomal gene 36B4 expression, as the internal control and WT mice on 
NCD as the control group for all in vivo experiments. For in vitro experiments, we used the 
same housekeeping gene and the controls were non-stimulated primary cells from WT 
mice. 
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Table 2.1. List of murine oligonucleotide sequences 
Gene Sense Anti-sense 
36B4 TCTGGAGGGTGTCCGCAAC CTTGACCTTTTCAGTAAGTGG 
Pparg GCATGGTGCCTTCGCTGA TGGCATCTCTGTGTCAACCATG 
Ppara CGGGAACAAGACGTTGTCAT CAGATAAGGGACTTTCCAGGTC 
Pgc1a CCC TGC CAT TGT TAA GAC C TGC TGC TGT TCC TGT TTT C 
Cd36 TTG TAC CTA TAC TGT GGC TAA ATG AG CTT GTG TTT TGA ACA TTT CTG CTT 
Cpt1b CATCCCAGGCAAAGAGACA AAGCGACCTTTGTGGTAGACA 
Acadm TGT CGA ACA CAA CAC TCG AAA CTG CTG TTC CGT CAA CTC AA 
Cox4i1 TCACTGCGCTCGTTCTGAT CGATCGAAAGTATGAGGGATG 
IL15 CCCATGTCAGCAGATAACCA GAGCTGGCTATGGCGATG 
TNFa CGTCGTAGCAAACCACCAAG GAGATAGCAAATCGGCTGACG 
iNOS AATCTTGGAGCGAGTTGTGG CAGGAAGTAGGTGAGGGCTTG 
F4/80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
Cd68 CTTCCCACAGGCAGCACAG AATGATGAGAGGCAGCAAGAGG 
Ccl5 TGCAGAGGACTCTGAGACAGC GAGTGGTGTCCGAGCCATA 
Ccl2 CAGGTCCCTGTCATGCTTCT GTGGGGCGTTAACTGCAT 
Cxcl10 CCAAGTGCTGCCGTCATTTTC GGCTCGCAGGGATGATTTCAA 
 
2.13. Graphs and statistical analysis 
The graphs and statistical analyses were performed using GraphPad Prism 6 software 
from GraphPad Software, San Diego, USA. The values are presented as mean +/- 
standard error (Ridaura, V.K. et al.). The statistical significance (p value) was calculated 
by non-parametric comparison between two groups (Mann Whitney test) or two-way 
ANOVA with Tukey's multiple comparisons test.  
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3. RESULTS 
3.1. IL-15 promotes weight gain and fat accumulation in the liver 
Given the proposed role of inflammation in NAFLD development, we examined the role of 
IL-15 in the development of hepatic steatosis. To this end, aged-matched wild type and 
Il15-/- mice were fed either NCD or HFD for 16 weeks. HFD is widely used to promote 
hepatic steatosis and NASH in rodents (Nakamura, A. and Terauchi, Y., 2013). We first 
evaluated whether HFD induces weight gain and fat accumulation in the liver. While the 
weight gain in the WT mice was significantly higher when maintained on HFD, Il15-/- mice 
did not show significant differences in body weight or liver mass when maintained on 
HFD. These observations suggest that IL-15 contributes to the diet-induced increase in 
body weight and liver mass in WT mice (Fig.3.1.A).  
Serum levels of cholesterol and non-esterified fatty acids (NEFA) are used as clinical 
indices of NAFLD severity (Okada, Y. et al., 2013). The levels of circulating cholesterol 
and NEFA were increased in WT-HFD mice, but not in Il15 null mice (Fig.3.1.B). 
Moreover, livers from mice fed with NCD exhibited normal hepatic architecture whereas 
the livers from HFD fed mice, revealed extensive microvesicular and macrovesicular 
steatosis. In contrast, lipid deposition in the liver parenchyma was absent in Il15-/- mice 
after HFD (Fig.3.1.C). 
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Figure 3.1.A: IL-15 deficiency prevents weight gain in the liver and hepatic fat 
accumulation. 
Body mass and liver weight were measured in mice maintained on either normal control 
diet (NCD) or high fat diet (HFD) for 16 weeks. Values are expressed as mean ± SD. 
Mann Whitney test N=4-8; p< 0.01(**), p<0.001(***), ns (not significant).  
 
  
Figure 3.1.B: HFD results in increased circulating levels of cholesterol and NEFA in 
wild type mice, but not in Il15 deficient mice. 
Cholesterol and NEFA levels were measured in the sera from mice maintained on NCD or 
HFD for 16 weeks. Values are expressed as mean ± SD. Mann Whitney test N=4-8; p< 
0.05(*), ns (not significant).  
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Figure 3.1.C: IL-15 deficiency prevents hepatic fat accumulation 
Sections of liver tissues collected from the indicate mice maintained on NCD or HFD for 
16 weeks were stained with hematoxylin and eosin (H&E) (left panels) or Sudan Black 
(right panels). Representative images from at least 4 mice for each group are shown. 
Magnification 10X. 
 
3.2. IL-15 deficiency reduces Pparg and increases Ppara induction after HFD 
The above results showed that Il15 knockout mice were relatively resistant to diet-induced 
fat accumulation in the liver. Therefore, we studied the possible role of IL-15 in the 
metabolic behavior of hepatocytes upon HFD. We examined the expression of 
transcription factors which are implicated in obesity-related pathologies. PPARs are 
ligand-dependent transcription factors and three members of this family have been 
identified, namely PPARα, PPARβ/δ, and PPARγ (Aprile, M. et al., 2014). PPARγ is the 
master regulator of adipogenesis, since it regulates the transcription of a wide number of 
genes involved in cellular differentiation and lipid accumulation (Aprile, M. et al., 2014). 
PPARγ coactivator 1-alpha (PGC1α), permits the interaction of PPARγ protein with 
multiple transcription factors, and has been related to metabolic dysfunction in 
mitochondria (Zhang, Y. et al., 2004). On the other hand, it has been shown that Ppara 
deficiency is related to the development of liver pathologies in different contexts (Li, H.H. 
et al., 2014). Our results showed that induction of Pparg mRNA was significantly higher in 
WT mice than in Il15-/- mice maintained on HFD, while Pparα levels were increased in KO 
mice (Fig.3.2). Although the expression of Pgc1α also showed a tendency to increase in 
Il15 
-/-
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Il15-/- mice following HFD, it was not statistically significant. These results indicated that 
the induction of Pparg gene by HFD in the liver is dependent on the availability of IL-15. 
 
 
 
Figure 3.2: IL-15 deficiency reduces Pparg and increases Ppara induction after HFD. 
Pparg, Pgc1a and Ppara RNA levels were evaluated in liver samples from WT or Il15-/- 
mice after 16 weeks in NCD or HFD. Values are expressed as the means ± SD. Tukey's 
multiple comparisons test; N=4; p< 0.05(*), p<0.01(**), ns (not significant). 
 
3.3. IL-15 regulates β-oxidation 
To verify whether IL-15 has a role in FA metabolism, we evaluated the expression of FA 
transporters and the enzymes involved in lipid metabolism in the liver. We found that HFD 
induced a significant increase in the expression of Cd36, the transporter of lipids across 
the plasma membrane, in WT mice compared to the Il15 null mice in the same diet 
(Fig.3.3.A). The transfer of lipids into to the mitochondria is mediated by carnytyl palmitoyl 
transferase (Cpt1a). The reaction catalized by this enzyme is considered as the first step 
in β-oxidation and one of the main regulatory checkpoints in FAs oxidation. We observed 
that hepatic Cpt1a expression was increased by HFD in control mice.  Interestingly, Il15-/- 
mice showed elevated Cpt1a expression in the liver at steady state that was further 
augmented by HFD (Fig 3.3.B).  
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Figure 3.3.A: HFD induces the expression of Cd36 in the liver.  
The expression of Cd36 in the livers from WT or Il15-/- mice after 16 weeks in NCD or HFD 
was evaluated by qPCR. Values are expressed as the means ± SD. Mann Whitney test 
N=4; p< 0.05(*).  
 
 
Figure 3.3.B: Cpt1a levels are increased in Il15-/- mice in NCD. 
The expression of Cpt1a in mice livers from WT or Il15-/- mice after 16 weeks in NCD or 
HFD was evaluated by qPCR. Values are expressed as the means ± SD. Mann Whitney 
test N=4; p< 0.05(*), p< 0.01(**). 
 
Next, we evaluated the induction of Acadm, the enzyme that catalyzes the first 
mitochondrial reaction for medium-chain FAs. HFD induced comparable levels of the 
enzyme in wild type and Il15-/- mice (Fig. 3.3.C). These results suggest that HFD-induced 
IL-15 may promote FA uptake by hepatocytes without affecting its utilisation in the 
mitochondria. 
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Figure 3.3.C: HFD induces Acadm expression in the liver. 
Mice were kept in NCD or HFD for 16 weeks and liver samples were used to evaluate 
Acadm transcription by qPCR. Data represents the mean fold induction and SEM. Mann 
Whitney test N=8-4; p< 0.05(*); ns (not significant). 
 
3.4. IL-15 suppresses mitochondrial respiration in mice primary hepatocytes  
FAs oxidation is a metabolic process that takes place in mitochondria. Hence, a potential 
increase in mitochondrial activity might promote fat degradation. We measured the 
transcript levels of the subunit 4 of cytochrome c oxidase (Cox4i1), the terminal enzyme in 
the mitochondrial respiratory chain. COX4i1 is a multi-subunit enzyme complex that 
couples the transfer of electrons from cytochrome c to molecular oxygen, and it is often 
used as an index of the functionality of the total respiratory chain complex (Li, Y. et al., 
2006). We found that Il15 deficiency did not affect cytochrome c oxidase mRNA levels 
(Fig.3.4.A). 
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Figure 3.4.A: IL-15 deficiency does not affect cytochrome c oxidase levels  
Mice were kept in NCD or HFD for 16 weeks and liver samples were used to evaluate 
Cox4i1 expression by qPCR. Data represents the mean fold induction and SD. Mann 
Whitney test N=8-4; ns (not significant). 
 
 
In tissues with comparable numbers of mitochondria and respiratory complex, the 
metabolic response can be variable depending on the stimuli. Changes in substrate 
utilization and reduced mitochondrial respiratory capacity following exposure to HFD are 
the key components in the development of obesity-related metabolic disease (Morris, E.M. 
et al., 2013). In order to elucidate whether endogenous IL-15 can play a role in the 
metabolic response of hepatocytes, we examined the mitochondrial respiration in primary 
hepatocytes isolated from WT and Il15-/- mice (Fig.3.4.B left) 
Spare respiratory capacity (SRC) is an extra capacity available for cells to produce energy 
in response to increased stress or work and as such is associated with cellular survival 
(van der Windt, G.J. et al., 2012). SRC is determined by the difference between maximum 
respiration and basal respiration in a given experimental condition. We found that Il15 null 
primary hepatocytes displayed a higher SRC compared to WT primary hepatocytes (Fig. 
3.4.B. right). Due to technical problems with the SeaHorse analyzer, I could not repeat the 
experiment to carry out the statistical analysis of the data.  
Since oxidative metabolism is a key pathway for FA degradation, we evaluated oxygen 
consumption after providing exogenous FAs to primary hepatocytes. We observed that 
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while palmitate supplementation did not increase oxygen consumption rate in WT primary 
hepatocytes, Il15-/- hepatocytes showed a significant increase in oxygen consumption rate 
(OCR) (Fig.3.4.C). Collectively, the above results indicate that endogenous IL-15 
attenuates FA oxidation in hepatocytes leading to fat accumulation in the liver.   
  
               
Figure 3.4.B: IL-15 deficiency increases mitochondrial respiration. 
Mice primary hepatocytes were kept in culture for 4 days and mitochondrial stress test 
(SeaHorse) was performed following manufacturer’s instructions. Mitochondrial respiration 
profile (left) is representative of two independent experiments. Spare respiratory capacity 
is represented as mean ± S from two data sets.  
 
 
Figure 3.4.C: IL-15 deficiency enhances fatty acid oxidation in hepatocytes 
Mouse primary hepatocytes were cultured for 4 days. Palmitate-BSA or BSA alone was 
added just before the assay. Seahorse mitochondrial stress test was performed according 
to manufacturer’s instructions. Data is represented as mean± SD. Mann Whitney test 
N=2; p< 0.05(*). 
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3.5 HFD induces Il15 expression in the liver  
The above finding that IL-15 deficiency protects against fat accumulation in the liver and 
that IL-15 deficient hepatocytes showed increased oxygen consumption upon addition of 
FAs suggested that HFD might induce Il15 expression within the liver. Evaluation of Il15 
gene expression revealed significant increase in hepatic Il15 mRNA levels in WT mice 
maintained on HFD (Fig.3.5). As expected, we did not detect the expression of Il15 in Il15 
-/- mice.  
 
 
Figure 3.5: Il15 mRNA levels are increased in WT mice in HFD. 
The expression of Il15 in livers from WT or Il15-/- mice after 16 weeks on NCD or HFD was 
evaluated by qPCR. Values are expressed as the means ± SEM. Mann Whitney test N=4; 
p< 0.01(**).  
 
3.6. HFD promotes the expression of pro-inflammatory mediators in the liver. 
The altered production of pro-inflammatory molecules has been implicated in the 
metabolic complications of obesity. For example, adipose tissue from obese individuals 
show increased expression of pro-inflammatory proteins such as TNF-α and iNOS 
compared to lean subjects (Weisberg, S.P. et al., 2003). Similarly, we found that while 
HFD induced elevated levels of TNF-α and iNOS in the liver of WT, while such increases 
were not observed in the livers of Il15-deficient mice (Fig.3.6). 
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Figure 3.6: HFD induces Tnfα and iNOS expression in the liver. 
mRNA levels were evaluated in liver samples from WT or Il15-/- mice after 16 weeks on 
NCD or HFD. Values are expressed as the means ± SEM. Tukey's multiple comparisons 
test; N=4; p< 0.05(*), p<0.01(**). 
 
3.7. HFD-induced macrophage infiltration in the liver is reduced in the absence of 
IL-15 
Macrophages are the most studied immune cells in the context of obesity and NAFLD. 
Their infiltration in different tissues have been related with insulin resistance, type 2 
diabetes and other complications of metabolic syndrome and obesity (Sell, H. et al., 
2012). We found a higher infiltration of macrophages in the liver of HFD-fed WT mice (Fig 
3.7.A). We further evaluated the macrophage infiltration in the liver of Il15-/- mice using 
qPCR for two macrophage markers, Cd68 and F4/80. We found that while HFD induced 
macrophages infiltration in the liver of WT mice, Il15-/- on HFD mice showed reduced 
expression of oF4/80 and Cd68 in the liver (Fig. 3.7.B) 
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Figure 3.7.A HFD increases macrophages infiltration in the liver. 
Mice were kept in NCD or HFD for 16 weeks, liver tissues were embedded in OCT and 
immunofluorescence staining was performed using anti-CD68 antibody to detect 
macrophage infiltration in the tissues (red arrows indicate macrophages). 
 
 
  
Figure 3.7.B: Expression of macrophages markers is increased in WT mice 
maintained on HFD.  
Mice liver tissues were collected after 16 weeks in normal control diet (NCD) or high fat 
diet (HFD) and qPCR for F4/80 and Cd68 was performed. Values are expressed as the 
means ± SEM. Mann Whitney test N=4-8; p< 0.05(*). 
 
 
3.8. HFD increases immune cells infiltration in mice liver 
Diet-induced obesity is considered as a main cause of NAFLD. Accumulating evidences 
indicate that NAFLD is strongly related to inflammation (Asrih, M. and Jornayvaz, F.R., 
2013). To examine the effects of HFD on the intra-hepatic lymphocytes (IHL), we 
maintained male WT mice on HFD for 16 weeks and we isolated IHL as described in the 
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Methods sections (Chapter 2). Due to problems with the availability of sufficient numbers 
of male mice, we did not carry out the analysis of livers of Il15-/- mice on HFD. First, we 
determined the effect of HFD on the total number of IHL in the liver. WT mice fed with 
HFD showed a significant increase in total IHL compared with those on NCD (Fig. 3.8.A). 
To identify the lymphocytes subsets that were increased in mice maintained on HFD, we 
carried out a phenotypic analysis of the IHLs. Splenocytes from the same mice served as 
controls. In this experimental model, we observed that there was no significant difference 
in the total numbers or the frequency of CD4+, CD8+ T cells, NK cells and NKT cells 
between the spleens of mice maintained on NCD or HFD (Fig. 3.8.B left panel). Although 
the total number of IHLs was increased in the mice maintained on HFD, we did not 
observe any significant differences in the relative percentage of intra-hepatic CD4+ and 
CD8+ T cell subsets. However, within the CD8+ T cells, the frequency of naïve CD8+ T cell 
subset (CD62Lhigh, CD44low) was decreased with a concomitant increase in the effector 
CD8+ population (CD62Llow, CD44high) in the livers of mice maintained on HFD (Fig.3.8.B , 
right panel).  
NK cells constitute a major proportion of mononuclear cells in the liver (Li, Z. and Diehl, 
A.M., 2003). We assessed whether differences in the NK and NKT cell subsets 
contributed to the observed increase in the total number of IHLs in HFD fed mice. The 
total number of innate NK cells (NK1.1+ CD3-) was increased in the liver of WT mice 
maintained on HFD. While the frequency of NKT cells (NK1.1+ CD3+) was not different, 
their total numbers were increased (Fig.3.8.A and Fig.3.8.B right panel). The frequency of 
iNKT (CD3+ CD1d: galcer tetramer+) cell subset, that has been shown to be decreased in 
the peripheral circulation of obese patients (Lynch, L. et al., 2012), was decreased in the 
livers of WT mice maintained on HFD. (Fig.3.8.B, right panel). Despite the differences in 
the frequency of the various subsets mentioned above, the total number of cells from each 
subset, except iNKT, showed a significant increase in the liver of HFD-fed mice 
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(Fig.3.8.B.). These results suggest that the HFD regimen enhances the recruitment and/or 
maintenance of the IHLs.  
 
 
Figure 3.8.A: HFD induce lymphocytes infiltration in the liver. 
Mice were maintained on NCD (N) or HFD (H) for 16 weeks and IHLs were isolated.  The 
total number of lymphocytes was determined in each experiment and the cell number for 
each subset was calculated. Data are pooled from three independent experiments (mean 
± SD). Mann Whitney test,  p< 0.05(*), p< 0.01(**), p<0.001(***). 
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Figure 3.8.B: HFD induces CD8+ T cell activation and NK cell infiltration in the liver. 
Mice were maintained on NCD or HFD for 16 weeks and IHL isolation was performed. 
Representative data from three independents experiments are shown. 
 
3.9. HFD induced chemokine gene expression in the liver is mediated by IL-15.  
The hyper-lipidic diet used in our experiments induced the infiltration of immune cells in 
the liver. The infiltration of immune cells can be promoted by an increased secretion of 
chemokines, which are important mediators of the inflammatory process (Lalor, P.F. et al., 
2007). During the immune response, chemokines facilitate the extravasation of leukocytes 
from the blood to the site of injury. Chemokine receptors on leukocytes sense the 
increasing chemotactic concentration gradients and facilitate cellular motility towards them 
(Rutkowski, M.D. and DeLeo, J.A., 2002). We found that transcript levels of Ccl2 (MCP-1), 
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Ccl5 (RANTES) and Cxcl10 (IP-10) were increased in the liver of WT mice on HFD but not 
in Il15-/- mice (Fig.3.9), indicating that HFD induces hepatic chemokine gene expression 
via IL-15. Ccl2 induces monocyte/macrophage chemotaxis, whereas Ccl5 promotes T cell 
recruitment and activation of NK cells. Cxcl10 is a chemoattaractant for 
monocyte/macrophages and T cells and promotes T cell adhesion to endothelial surfaces 
(Braunersreuther, V. et al., 2012). 
 
Figure 3.9: HFD induced chemokine mRNA expression in the liver requires IL-15. 
Mice were kept on NCD or HFD for 16 weeks and the expression of Ccl2, Ccl5 and 
Cxcl10 in the liver was measured by qPCR. Data represents mean ± SD from 4-8 mice 
per group. Mann Whitney test; p< 0.05(*).  
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3.10. IL-15 induces chemokines expression in mice primary hepatocytes  
To evaluate if IL-15 directly induce the transcription of chemokines in hepatocytes, we 
stimulated primary hepatocytes from WT mice with IL-15. Hepatocytes from Il15ra-/- mice 
lacking the ligand binding IL-15Ra subunit served as controls. We observed that IL-15 
induced Ccl5 and Cxcl10 transcription in WT hepatocytes, whereas the induction for Ccl2 
was not significant. Induction of Ccl5 was clearly dependent on the presence of Il15ra in 
hepatocytes, while induction of Cxcl10 after IL-15 stimulation was not dependent on Il15ra 
(Fig. 3.10).  
   
 
Figure 3.10: IL-15 induces Ccl5 and Cxcl10 expression in mouse primary 
hepatocytes. 
Primary hepatocytes were stimulated with IL-15 (20ng/ml) for 2 hours in starving medium. 
The expression of Ccl5, Cxcl10 and Ccl2 was evaluated by quantitative PCR. Data 
represents mean ± SEM from three independent experiments. Mann Whitney test p< 0.05, 
p< 0.001, ns (not significant). 
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3.11. IL-15 and IL-5Rα are required for the maintenance of NK populations in the 
liver 
It is well established that the maintenance of the CD8+ T and NK cell subsets in the liver is 
mediated by IL-15. Therefore, we examined whether the absence of IL-15 signalling would 
affect lymphocyte homeostasis in the liver. To this end, we characterized the IHL 
populations in age-matched WT, Il15-/- and Il15ra-/- mice.  In agreement with previous 
reports, splenic CD8+ T cells were reduced in the absence of IL-15 or its receptor alpha 
subunit. Interestingly, there were no differences in the percentage of intra-hepatic CD8+ T 
cells (Fig.3.11.A). However, there was a 6-fold reduction in the NK cells in the livers of 
Il15-/- and Il15ra-/- mice. A similar reduction was also observed in the intra-hepatic NKT 
and iNKT cell subsets (Fig.3.11.B and C)  
 
 
Figure 3.11.A: Splenic but not liver CD8+ T cells are dependent on IL-15 signaling. 
Spleen and IHL isolation was performed in age matched WT, Il15-/- and Il15ra-/- mice. T 
cells were characterized by FACS analyses. Data represent four independents 
experiments. 
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Figure 3.11.B: NK and NKT cells are reduced in the absence of IL-15 or IL-15Rα. 
Lymphocytes were isolated from spleen and liver of age matched WT, Il15-/- and Il15ra-/- 
mice and phenotyped for NK an NKT cells using the appropriate markers. Data are 
representative of four independent experiments. 
 
 
 
Figure 3.11.C: IL-15 and IL-15Rα are needed for iNKT cell maintenance in the liver. 
Lymphocytes were isolated from spleen and liver of age matched WT, Il15-/- and Il15ra-/- 
mice and phenotyped for iNKT cells using the appropriate markers. Data are 
representative of four independent experiments. 
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3.12. IL-15Rα expression in both macrophages and hepatocytes contribute to NK 
cell maintenance in the liver 
IL-15Rα, the high affinity receptor for IL-15, increases the biological activity of IL-15. The 
presence of IL-15Rα in different cells types can influence the homeostasis of immune 
populations mainly TCD8 and NK (Mortier, E. et al., 2009). In order to elucidate the 
specific cell types that express IL-15Rα and contribute to NK cell maintenance in the liver, 
we evaluated NK cell infiltration in the absence of IL-15Rα in the macrophages. NKT cells 
population in the liver was significantly lower in the absence of Il15ra in the macrophages, 
but the reduction in NK or iNKT was not significant (Fig. 3.12.A). Spleen was used as a 
control, and a subtle reduction in NK and NKT cells was observed in the absence of IL-
15Ra in macrophages. 
Hepatocytes represent around the 80% of total cells in the liver (Okada, Y. et al., 2013). 
Thus, we evaluated the impact of IL-15Rα expression in hepatocytes on the homeostasis 
of NK, NKT and iNKT cells. Remarkably, we observed that IL-15Rα in the hepatocytes 
was indispensable for NK, NKT and iNKT maintenance in the liver (Fig. 3.12.B)  
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Figure 3.12.A: IL-15Rα expression in macrophages is required for NKT cells 
maintenance in the liver. 
Splenic and liver lymphocytes were isolated from mice lacking IL-15Ra in macrophages 
(Il15rafl/fl LysM-Cre+) and control littermates (Il15rafl/fl LysM-Cre-). Data in the upper panel 
are representative of 4 independent experiments. In the lower panels values are 
expressed as mean ± SD. Mann Whitney test; p< 0.05( *). 
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Figure 3.12.B: IL-15Rα expression in the hepatocytes is required for the 
maintenance of NK, NKT and iNKT cells in the liver. 
Splenic and liver lymphocytes were isolated from Il15ra hepatocytes-deficient mice 
(Il15rafl/fl Alb-Cre+) and control littermates (Il15rafl/fl Alb-Cre-). Data in the upper panel 
represent three independent experiments. In the bottom panel values are expressed as 
the mean ± SD. Mann Whitney test p< 0.05(*), p<0.01(**). 
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3.13 Summary of results 
 
In this thesis we described a new role for IL-15 in fatty liver disease. We found that IL-15 
promotes weight gain and fat accumulation in the liver by modulating liver metabolism. 
Moreover, we showed that IL-15 decreased mitochondrial FAs oxidation in hepatocytes. 
Furthermore, in the context of NAFLD, we showed the role of IL-15 in induction of 
chemokines in the liver. Additionally, we found that IL-15Ra expression in hepatocytes is 
indispensable for NK cells homeostasis in the liver. Overall, our results contribute to a 
better understanding of obesity-associated inflammation.  
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4. DISCUSSION 
Obesity-associated metabolic syndrome represents a cluster of metabolic diseases 
including type 2 diabetes mellitus, cardiovascular disease and NAFLD. Sedentary lifestyle 
and increased food intake are the major predisposing factors in obesity. Obesity 
associated inflammation is characterized by immune cell infiltration in the affected tissues, 
which induces local and systemic increase in pro-inflammatory cytokine levels, eventually 
leading to the development of insulin resistance (Sell, H. et al., 2012).  
NAFLD is considered as the most common cause of chronic liver disease in western 
countries and is associated with systemic and hepatic insulin resistance. NAFLD has a 
wide histological spectrum ranging from ‘simple’ steatosis to nonalcoholic NASH, which 
may progress to cirrhosis (Zhan, Y.T. and An, W., 2010). In this thesis we evaluated the 
role of IL-15, an immuno-inflammatory cytokine in the progression of the liver 
manifestation of obesity, namely NAFLD. 
Following the HFD regimen, body and liver weight are increased in WT but not in Il15-/- 
mice, indicating that IL-15 plays a crucial role in diet-induced obesity and fatty liver 
disease.  The HFD regimen also increased the circulating levels of cholesterol and NEFA 
in WT mice but not in IL-15 deficient mice. Elevated level of cholesterol is one of the 
manifestations of disorders in lipoprotein metabolism know as dyslipidemia, which 
promotes insulin resistance. Other parameters used to characterize dyslipidemia are the 
elevated low-density lipoprotein cholesterol (LDL) and triglyceride levels, or decreased 
high-density lipoprotein cholesterol (HDL) (Plana, N. et al., 2014). An increase in 
circulating NEFA may contribute to NAFLD development in obese subjects. Triacylglycerol 
(TG) stored in adipose tissue is hydrolyzed to NEFA to be transported to target tissues for 
utilization. In the fasting state, plasma NEFAs are derived mainly from hydrolysis of TG in 
adipocytes. After a meal, lipoprotein lipase (LPL) in the capillaries of adipose tissue 
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hydrolyses circulating TG, mainly the dietary fat carried in the chylomicrons, and this is an 
additional route of generation of plasma NEFA (Karpe, F. et al., 2011). NEFAs from 
adipose tissue can be used as an energy source by many tissues, including liver and 
skeletal muscle. In hepatocytes, their fate differs depending on energy needs, hormone 
balance and substrate availability, i.e. they can be re-packaged into TGs and exported as 
very low density lipoproteins (VLDL), stored within the liver, or converted to ketones 
(Nguyen, P. et al., 2008). The excess of TG produced in the liver are stored as fat within 
hepatocytes, leading to lipid deposition observed in fatty liver diseases (Browning, J.D. 
and Horton, J.D., 2004). The increased microvesicular and macrovesicular fat deposition 
in the liver parenchyma of WT mice after HFD, but not in Il15-/- mice indicates that IL-15 
promotes lipid deposition in the liver under dietary conditions that promote obesity.  
Day and James have proposed that while lipid deposition in the liver is the first of the 2 
‘hits’ needed for NASH development, the second hit represents all the factors that 
contributes to liver inflammation (Day, C.P. and James, O.F., 1998). Our results show that 
IL-15 promotes diet-induced NAFLD by modulating lipid metabolism in the liver, as well as 
by perpetuating the inflammatory responses in the liver. 
Lipid metabolism is controlled by different transcription factors. These include Srebpf1 
(sterol-regulatory-element-binding protein), Cepba (CCAAT/enhancer binding protein) and 
factors that regulate with lipid storage and utilization, namely Pparg, which promotes lipid 
storage, and Ppara, which directs FA oxidation (Wheeler, M.C. and Gekakis, N., 2014). 
FAs, absorbed from diet or generated in adipose tissues lipolysis, as well as 
prostaglandins are natural ligands of PPAR family of transcription factors (Vega, R.B. et 
al., 2000). We found a reduction in Pparg expression in Il15-/- mice after HFD compared to 
WT mice. Previous reports showed that hepatocyte- or macrophage- specific deletion of 
Pparg protects mice against diet-induced hepatic steatosis, suggesting a pro-steatotic role 
of PPARγ in parenchymal and non-parenchymal cells (Moran-Salvador, E. et al., 2011). 
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Therefore, the reduced Pparg expression in the liver of IL-15 deficient mice on HFD could 
contribute, at least partly, to reduced hepatic lipid storage in these mice.  
In contrast to Pparg, Ppara gene expression is increased in the livers of IL-15 deficient 
mice under HFD regimen, suggesting a possible increase in FAs oxidation in the liver of 
KO mice. Metabolically active tissues such as liver, muscle, intestine, and brown adipose 
tissue expresses high levels of PPARα. Specifically in hepatocytes, PPARα expression 
levels are very high, possibly to increase β-oxidation that reduces lipid storage in the liver 
(Lefebvre, P. et al., 2006). Methionine choline-deficient diet results in liver injury similar to 
human NASH. Ppara deficient mice fed with this diet develop severe hepatic steatosis and 
steatohepatitis. Consequently, PPARα agonist treatment reverses steatohepatitis in mice 
with established NASH (Lefebvre, P. et al., 2006). Hence, increased Ppara expression in 
the liver of IL-15 KO mice on HFD, could act in synergy with reduced Pparg expression to 
prevent hepatic fat deposition.  
PPARα has also been described as a transcriptional regulator of inflammatory response in 
various tissues, including liver by inhibiting the inflammatory genes induced by NF-κB 
(Tailleux, A. et al., 2012). The increase in Ppara levels that we observe the KO mice can 
also control the inflammatory response by IL-15 in NAFLD.  
We also evaluated the expression of Pgc1a, the PPARγ co-activator, which allows the 
interaction of PPARγ with multiple transcription factors (Zhang, Y. et al., 2004). This co-
activator was initially described as a positive regulator of PPARγ target genes expression 
(Puigserver, P. et al., 1998). However, we did not find any significant increase in Pgc1a 
expression in the livers of WT mice under HFD regimen, despite a significant increase in 
Pparg expression. Pgc1a is also capable of co-activating Ppara in the transcriptional 
control of genes regulating enzymes involved in FA oxidation (Vega, R.B. et al., 2000). 
The livers of IL-15 deficient mice on HFD also showed a tendency to upregulate Pgc1a, 
although this was not statistically significant.  Thus, the decreased hepatic lipid 
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accumulation in Il15-/- mice maintained on HFD could results from the combined effects of 
reduced lipid uptake due to downregulation of Pparg and increased FAs degradation 
stimulated by Ppara expression, and a possible co-operation between Ppara and Pgc1a. 
Hepatic steatosis can be a consequence of increased lipid synthesis and/or lipid uptake, 
via overexpression of the FAs transporters. CD36 is a plasma membrane lipid transporter 
is under the transcriptional control of PPARγ, and has been related to fat accumulation in 
the liver (Wheeler, M.C. and Gekakis, N., 2014). 
WT mice in HFD showed high expression of Cd36, consistent with lipid deposition within 
the hepatocytes, also known as microvesicular fat deposition. However, Cd36 increase 
after the HFD regimen was significantly less in Il15-/- mice than in WT mice, suggesting 
that IL-15 promotes FAs intake by liver cells.  
Within cells, FAs are catabolized by β-oxidation mainly in the mitochondria and also in 
peroxisomes to generate energy. β-oxidation of the bulk of short-, medium-, and long-
chain FAs derived from diet take place in mitochondria, and the main enzymes 
responsible for this process are localized in the cristae and in the matrix (Reddy, J.K. and 
Hashimoto, T., 2001). The genes encoding enzymes involved in the beta-oxidation 
pathway in liver are transcriptionally regulated by PPARα. The initial step in mitochondrial 
FAs oxidation is the translocation of FA from cytosol to the matrix. This step is catalyzed 
by sequential enzymatic reactions mediated by CPT1, CPTII and carnitine-acylcarnitine 
translocase. Cpt1a is a key enzyme in the carnitine-dependent FA transport across the 
mitochondrial inner membrane and its deficiency results in a decreased rate of FA β-
oxidation (Assimacopoulos-Jeannet, F. et al., 1997). Whereas HFD induced the 
expression of the liver-specific isoform of Cpt1a in WT mice, the IL-15 KO mice showed 
an elevated basal expression even under normal diet. This observation suggests that IL-
15 is available even under normal steady state, and that it attenuates FA oxidation in the 
liver at the level of FA import into the mitochondria.  
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β-oxidation of FA within mitochondria is initiated by acyl-CoA dehydrogenases. Deficiency 
of Acadm, a medium-chain acyl-CoA dehydrogenase induces different metabolic 
abnormalities, such as hepatic dysfunction and fasting hypoglycemia. (Matern, D. and 
Rinaldo, P., 1993). Lipid-rich diet induced Adcam mRNA in both WT and IL-15 KO mice to 
a comparable level. Collectively, IL-15 appears to attenuate FA utilization at the level of 
lipid transport through plasma membrane (Cd36) and the FAs transfer into the 
mitochondria (Cpt1a).  
Lipid oxidation within mitochondria is dependent on mitochondrial respiratory capacity, 
which is controlled by several factors, including the synthesis, assembly and functioning of 
the respiratory chain complex. For example, cytochrome c oxidase exerts a tight control 
on mitochondrial function. The COX IV protein is essential for the assembly of cytochrome 
c oxidase complex (Li, Y. et al., 2006). Both WT and IL-15 KO mice expressed 
comparable levels of Cox4i1 mRNA, suggesting that IL-15 does not affect the assembly of 
cytochrome c oxidase complex. However, direct measurement of the mitochondrial 
respiration profile of primary hepatocytes (SeaHorse), showed a higher maximum 
respiratory capacity in IL-15 deficient hepatocytes compared to WT hepatocytes (Fig. 
3.4.B). This observation indicates that the loss of IL-15 enhances the cellular capacity to 
increase oxidative metabolism under certain conditions, by boosting the oxygen 
consumption rate. One of those conditions could be the excess lipids availability during 
the HFD regimen. Energy starvation enables primary hepatocytes to use exogenous FAs 
such as palmitate as energy source, via beta oxidation followed by Acetyl-CoA 
metabolism in the tricarboxylic acid cycle and oxidative phosphorylation. Under these 
conditions, the maximum oxygen consumption was increased in Il15-/- primary hepatocytes 
(Fig. 3.4.C)  
Collectively our results show that IL-15 deficiency attenuates the HFD-induced expression 
of genes involved in lipid uptake (Pparg, Cd36), but enhances the expression of genes 
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implicated in lipid utilization (Ppara) and FA transport into mitochondria (Cpt1a) as well as 
the basal and FA-induced OCR. These findings indicate that Il-15 induced during HFD 
regimen not only enhances hepatic lipid uptake but also attenuates its degradation via 
beta-oxidation and oxidative phosphorylation. 
 
Obesity is a low-grade inflammatory disease (Sell, H. et al., 2012). Several pro-
inflammatory cytokines have been associated with the metabolic complications involved in 
this pathology. IL-15 has been extensively studied as an inflammatory cytokine, critical for 
the development, homeostasis and functioning of the cells of the innate and adaptive 
immune system (Kanegane, H. and Tosato, G., 1996; Stoklasek, T.A. et al., 2006). 
Besides phagocytic cells, skeletal muscles express high levels of IL-15 mRNA. It 
suggested that IL-15 may function as a muscle-derived endocrine factor, or “myokine”, 
which can modulate body composition (Quinn, L.S. and Anderson, B.G., 2011). Other 
reports have also suggested that IL-15 is produced by the liver, in hepatocytes cell lines 
and by hepatoma cell lines (Golden-Mason, L. et al., 2004; Correia, M.P. et al., 2009). In 
this work, we show that IL-15 is constitutively expressed in the liver and is upregulated 
after 16 weeks in HFD. In agreement with these results, Quinn et.al., have shown that in 
mice susceptible to oxidative stress, obesigenic diet with high calcium significantly 
increased IL-15 mRNA expression in the visceral fat and skeletal muscle tissues (Quinn, 
L.S. and Anderson, B.G., 2011), but the cell types involved were not identified. Similarly, 
very little information is available on the expression of IL-15 at the mRNA and protein 
levels in different tissues under physiological conditions. Additionally, in agreement with a 
pathogenic role of IL-15 in obesity, circulating levels of IL-15 are increased in obese 
insulin resistant subjects and decreased after weigh loss (Christiansen, T. et al., 2010).  
In contrast to the above studies and our own findings, another study has reported a 
beneficial role of IL-15 in obesity reported before. Barra et al., found that Il15-/- mice 
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exhibit higher amounts of body fat than control mice (Barra, N.G. et al., 2010). Although 
the reasons for these completely contradictory conclusions are unclear, it is noteworthy 
that Barra et la., have observed anti-obesity effect of IL-15 on female IL-15 KO mice fed 
with NCD, whereas we observed the pro-obesity role of IL-15 in male IL-15 KO mice fed 
with HFD. As both mice strains are in C57BL/6 background, a possible explanation for 
these different findings could be the gender of the mice, the food regimen used, and 
influence by the gut microbiota. Diet is an important modulator of microbial diversity in the 
gut. Changes in gut microbiota are not only the consequence of obesity, but can also be a 
contributing factor because the obese phenotype can be transposed by gut microbiota 
transplantation, (Ridaura, V.K. et al., 2013). Nonetheless, as described earlier our in vitro 
data on isolated primary hepatocytes strongly support a pro-obesity role of IL-15, at least 
under conditions of excess dietary fat. 
Most of the studies on the influence of pro-inflammatory cytokines in obesity-associated 
pathologies have focussed on the adipose tissue. For example, TNF-α, IL-6, iNOS, TGF-
β1, C-reactive protein, soluble ICAM, and monocyte chemotactic protein-1 (MCP-1) are 
elevated in adipose tissues from obese subjects when compared to lean ones. Skeletal 
muscle tissue in obesity also produces elevated amounts of TNF-α and iNOS (Weisberg, 
S.P. et al., 2003). Deficiency in Tnfa or iNOS was reported to have a beneficial role on the 
insulin sensitivity in obese mice (Weisberg, S.P. et al., 2003). In the liver, it was reported 
that treatment with insulin-like growth factor (IGF) prevented liver failure by inhibiting TNF-
α production and reducing the induction of iNOS (Hijikawa, T. et al., 2008). We observed 
an upregulation of Tnfa and iNOS expression in the liver of WT obese mice that occurred 
concomitantly with Il15 gene induction. This upregulation of Tnfa and iNOS genes did not 
occur in the liver of IL-15 KO mice maintained on HFD (Fig. 3.6), suggesting that IL-15 
acts upstream of TNFa and iNOS in obesity-associated changes in gene expression in the 
liver.  
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Tissue macrophages play an important role in the development of obesity-associated 
inflammation. Several studies reveal a pathogenic role for adipose tissue-associated 
macrophages in metabolic abnormalities related to over nutrition (Sell, H. et al., 2012). 
Even though the role of liver macrophages (KCs) in fatty liver disease has not been 
extensively studied, high-fat or high-sucrose diet-induced steatosis and hepatic insulin 
resistance were reported to be prevented following depletion of KCs in the liver (Huang, 
W. et al., 2010). Moreover, this study also showed that TNF-α is partially responsible for 
KC-mediated alterations in hepatocyte FA oxidation, triglyceride accumulation, and insulin 
responsiveness (Huang, W. et al., 2010). 
We observed an increase in the macrophage infiltration in the liver parenchyma in WT 
mice fed with lipid-rich diet, and analysis of mRNA expression revealed low levels of 
macrophage markers (Cd68 and F4/80) in IL-15 KO mice on HFD (Fig. 3.7.B), suggesting 
that IL-15 may play a role in the recruitment of macrophages to the liver during the 
inflammatory conditions such as NAFLD. Accordingly, we observed upregulation of two 
macrophage chemotactic factors Ccl2 and Cxcl10 in WT mice fed with HFD but not in IL-
15 deficient mice. IL-15 is also known to activate macrophages; however the underlying 
mechanisms are unclear. Earlier reports showed that the effects of IL-15 on macrophages 
are dependent on the cytokine concentration (Alleva, D.G. et al., 1997). Whereas high IL-
15 concentrations enhanced pro-inflammatory (i.e., TNF-α, IL-1, and IL-6) and anti-
inflammatory (i.e., IL-10) cytokine production by macrophages, low concentrations 
suppressed pro-inflammatory, but not anti-inflammatory, cytokine release. Suppression 
induced by low IL- 15 concentrations is mediated by the high affinity IL-I5Rα, and high 
doses effects were mediated by the IL-2/IL-15Rβ (Alleva, D.G. et al., 1997). Clearly, 
further studies are needed to delineate the role of IL-15 in macrophage functions. 
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Healthy liver contains large number of lymphocytes, which include not only NK and NKT 
cells but also CD4 and CD8 T cells (Exley, M.A. and Koziel, M.J., 2004). In pathological 
conditions, there is an increase in lymphocytes in the liver parenchyma. Lymphocytes are 
mainly found at the sites of active damage and fibrogenesis in progressive disease (Lalor, 
P.F. et al., 2007). We found a massive increase in the total IHL induced by HFD in WT 
mice (Fig.3.8.B). While the frequencies of CD4+ and CD8+ T cell populations are not 
modified in the liver of WT mice after HFD, their total numbers are significantly increased 
as a consequence of lipid-rich diet (Fig.3.8). T cells are critical to the progression of liver 
disease (Lalor, P.F. et al., 2007). Even though CD8 and CD4 T cells are found in areas of 
parenchymal inflammation and fibrosis in steatohepatitis, their antigen specificity is not 
known. Some reports suggest that T cells recognize liver antigens generated by oxidative 
stress–induced modification and others postulate that T cells are derived from the 
circulation and have their own specificity (Lalor, P.F. et al., 2007). We found that effector 
CD8+ T cells (CD44high CD62Llow) are increased in the livers of WT mice fed with HFD, 
with the concomitant reduction in naïve population (CD44low CD62Lhigh) which was not 
reflected in the spleen of the same mice (Fig.3.8). These results suggest that under the 
experimental conditions of HFD-induced liver pathologies, liver-derived neo-antigens 
might activate CD8+ IHL. Alternatively, it is possible that these CD8+ T cells with activated 
phenotype are terminally differentiated effector cells that die in the liver by apoptosis 
(Mehal, W.Z. et al., 1999). Nevertheless, HFD promotes the infiltration of activated CD8+ 
T cells in the liver and these cells, in turn, can contribute to the inflammatory process. 
Given that HFD diet induces Il15 gene expression in the liver and that IL-15 is implicated 
in the homeostatic expansion of CD8+ T cells with memory phenotype, it is also possible 
that IL-15 may also be involved in their activation. The effect of IL-15 deficiency on the 
activation phenotype of intrahepatic CD8 T cells in HFD-fed mice remains to be studied. 
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In human subjects, hepatic NK cells were reported to be increased in NASH, but in 
established NAFLD their numbers were reduced (Kahraman, A. et al., 2010). The 
frequency and the total numbers of NK cells are increased in the liver of HFD-fed mice 
(Fig.3.8), suggesting these mice developed NASH. In the pathogenesis of NAFLD, hepatic 
NK cells may have two different roles. First, an anti-fibrotic effect mediated by the 
elimination of HSCs and second, activated NK cell-mediated killing of hepatocytes and 
cholangiocytes via TRAIL (tumor necrosis factor-related apoptosis-inducing ligand). 
Hepatocytes injury is one of the principal features of NASH, and is considered as one of 
the primary events mediating liver damage in this pathology (Zhan, Y.T. and An, W., 
2010). 
NKT cells are often divided into two groups: type I NKT cells, which express an invariant 
TCR (Vα14/ Jα18) and are readily detectable by α-galactosylceramide (α-GalCer)-loaded 
CD1d tetramers, and type II NKT cells which express a more diverse T-cell receptor 
repertoire and cannot be directly identified (Martin-Murphy, B.V. et al., 2014). In our 
experiments, we identified type I NKT cells as iNKT (CD3+ α-GalCer/CD1d tetramer +) 
and type II as NKT (CD3+ NK1.1+). Our results showed no changes in the frequency of 
NKT cells within IHL, but their total numbers are increased. Additionally, iNKT population 
is decreased within the CD3+ cells but the total numbers did not change after HFD (Fig. 
3.8). Published data about NKT infiltration in fatty liver is contradictory. In obese, leptin-
deficient ob/ob mice, NKT cells were reduced in the liver (Guebre-Xabier, M. et al., 2000). 
Other reports suggest that hepatic NKT cells can skew the local cytokine production 
towards Th2 cytokines rather than Th1, and as a consequence, depletion of NKT cells 
leads to Th1 polarization of hepatic cytokine production in a mouse model of obesity 
(Kremer, M. and Hines, I.N., 2008). Conversely, in patients with advanced NAFLD an 
increase in liver NKT cells has been observed (Tajiri, K. et al., 2009). Therefore, both 
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suppressive and inflammatory functions have been ascribed to NKT cells in an obese 
state.  
Recently, Martin-Murphy et al. reported that CD1d-/- mice displayed increased adiposity 
and greater induction of inflammatory genes in the liver (Martin-Murphy, B.V. et al., 2014). 
This study did not distinguish among NKT subtypes. However, as CD1d is required for 
positive selection of both Type I and Type II NKT cells in the thymus (Martin-Murphy, B.V. 
et al., 2014), CD1d−/− mice will lack both NKT subsets. The role of iNKT in obesity is also 
controversial. In adipose tissue of HFD-fed mice, iNKT cell activation causes impairment 
of metabolic functions through the release of pro-inflammatory cytokines and the 
recruitment of other pathogenic immune cells (Wu, L. et al., 2012). In contrast to this, 
iNKT cells were decreased after HFD in a mouse model, and in the circulation in obese 
patients (Lynch, L. et al., 2012). In line with this report the reduction in iNKT cells in the 
liver of HFD fed-mice, may suggest a protective role for this immune population in the 
basal state. 
Until now, we have shown that HFD increases the infiltration of many types of immune 
cells in the livers of WT mice, but not in IL-15-deficient mice. As memory (CD62Llow, CD44 
high) CD8+T cells, NK and NKT cells are dependent on IL-15 and are not detected in the 
secondary lymphoid organs of IL-15 deficient mice (Ring, A.M. et al., 2012), the reduction 
of these cell types in the liver is a direct consequence of IL-15 deficiency. In line with this 
assumption, the number of these cells is reduced in IL-15-deficient mice maintained on 
normal diet. Nonetheless, as IL-15 is induced by HFD, it is reasonable to propose that 
HFD-induced IL-15 within the liver and consequent modulation of IHL population would 
impact on the NAFLD. The phenotype of the infiltrating cells in the liver of IL-15 deficient 
mice on HFD needs to be evaluated in order to elucidate their contribution to NAFLD.   
Our finding that macrophages are also reduced in the livers of IL-15 KO mice needs to be 
explored further, as the role of IL-15 in the homeostasis of macrophages has not yet been 
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reported. Infiltration of immune cells to the site of inflammation (here the liver) is initiated 
by the expression of a variety of chemokines (Rutkowski, M.D. and DeLeo, J.A., 2002). 
For example, in alcoholic hepatitis, the expression of several CC and CXC chemokines 
including CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL5 and CXCL8, has been reported 
(Maltby, J. et al., 1996). On the other hand, chemokine and chemokines receptors 
expression in NAFLD and NASH is not well characterized, even though the inflammatory 
conditions are similar and likely to induce a similar spectrum of chemokines.  
We observed that increased levels of Ccl2, Ccl5 and Cxcl10 mRNA in the livers of mice 
fed with HFD (Fig.3.9). Indeed, serum CCL2/MCP1 levels are reported to be increased in 
steatosis, and Ccl2-deficient mice are protected from liver injury and fibrosis (Zamara, E. 
et al., 2007)  in agreement with our results in WT mice maintained on HFD (Fig.3.9).  
Similarly, CCL5/RANTES plays an important role in the progression of hepatic 
inflammation, and elevated hepatic Ccl5 expression was reported in a dietary model 
of NAFLD. Moreover, in patients with ultrasound-diagnosed NAFLD, CCL5 serum levels 
were elevated (Kirovski, G. et al., 2010). Expression of Cxcl10/IP10 is associated with 
accelerated progression of inflammatory liver disease following HCV infection (Lalor, P.F. 
et al., 2007). During NASH development, TNFα-producing KCs also produce Cxcl10 and 
Ccl2 promoting blood monocyte infiltration (Tosello-Trampont, A.C. et al., 2012). Our 
finding that the HFD-induced expression of hepatic Ccl2, Ccl5 and Cxcl10 mRNA did not 
occur in Il15-/- mice (Fig. 3.9) indicates that immune cell infiltration of the liver during HFD 
regimen is mediated by IL-15.  
In vitro study in primary human hepatocytes stimulated with palmitic acid showed a dose-
dependent lipid accumulation, and corresponding dose-dependent induction of Ccl5 
(Kirovski, G. et al., 2010). Others showed that incubation of irradiated hepatocytes in vitro 
with TNF-alpha or IL-1beta, led to the up-regulation of Ccl2 or Cxcl10 and Ccl2, 
respectively (Moriconi, F. et al., 2008). We also observed an increase in the expression of 
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Ccl5 and Cxcl10 in isolated primary hepatocytes following stimulation with IL-15, 
indicating that at least part of their expression in HFD-fed WT mice could be derived from 
hepatocytes. Whereas induction of Cxcl10 occurred in both WT and IL-15Ra KO 
hepatocytes, Ccl5 induction occurred only in WT primary hepatocytes (Fig.3.10). Hence, it 
appears that differential IL-15 signalling can occur in the presence or absence of IL-15Ra, 
leading to differential chemokine gene expression and possibly other functions. In contrast 
to Ccl5 and Cxcl10, IL-15 stimulation did not induce any significant expression Ccl2, 
suggesting that the expression of this chemokine in the total liver is mediated by other 
liver resident cells or is stimulated by another factors induced by IL-15 rather than directly 
by IL-15.  
Liver immune populations are enriched in NK and NKT cells, and to a lesser extent in 
CD8α+ T cells (Exley, M.A. and Koziel, M.J., 2004). As IL-15 is implicated in the 
development and homeostasis of these lymphoid cells, we hypothesize that IL-15 
availability and its signalling within the liver would profoundly influence the immune cell 
composition in the liver and that this would in turn modulate the inflammatory responses in 
the liver. Intriguingly, we observed that IL-15 or IL-15Rα deficiency reduced CD8+ T 
lymphocytes in the spleen as described previously (Kanegane, H. and Tosato, G., 1996; 
Lodolce, J.P. et al., 1998; Stoklasek, T.A. et al., 2006), but did not affect hepatic CD8+ 
cells (Fig. 3.11.A). Studies on hepatic CD8+ T lymphocytes in Il15-/- or Il15ra-/- mice are 
very limited. Moreover, evaluation of CD8+ T cells in the liver is confounded by the fact 
that they migrate to the liver following systemic activation, where they are trapped and 
eventually eliminated (John, B. and Crispe, I.N., 2004). The importance of IL-15 signaling 
in the maintenance of memory cells in the liver has been documented and memory CD8+ 
T cell cluster formation in the liver is dependent on IL-15 and IL-15Ra, like in bone marrow 
(Su, Y.C. et al., 2010). It remains to be studied whether Il-15 deficiency selectively affects 
the memory CD8 T cell subsets in the liver. 
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We showed that NK, NKT and iNKT cells are reduced in the livers of Il15-/- or Il15ra-/- mice 
when compared to WT mice (Fig 3.11.B & 3.11.C). These results are concurrent with the 
requirement of IL-15 for NK cell homeostasis and activation in lymphoid organs (DiSanto, 
J.P. et al., 1995; Lodolce, J.P. et al., 1998; Kennedy, M.K. et al., 2000; Gordy, L.E. et al., 
2011).  Recently, Pek et al., showed that administration of recombinant human IL-15 (rhIL-
15) or Ad-vector expressing hIL-15 to humanized mouse significantly enhanced NK cell 
development and maturation, particularly in bone marrow and liver (Pek, E.A. et al., 2011). 
Previous studies using macrophage specific Il15ra-/- mice reported that macrophage-
derived IL-15Rα maintains NK cells (NK1.1+ CD3-) homeostasis by supporting proliferation 
and maturation (Mortier, E. et al., 2009). We also evaluated NK cells in the liver of the 
same conditional KO mice, but additionally we characterized NKT and iNKT cells. We 
observed that while the NK and NKT populations in the liver were diminished in the 
absence of IL-15Ra expression in macrophages, iNKT cells did not (Fig. 3.12.A.). On the 
other hand, we observed that IL-15Ra deficiency in hepatocytes caused profound 
reduction in NK, NKT and iNKT cells in the liver (Fig. 3.12.B.). An in vitro study had shown 
that hepatocytes as well as IL-15 can induce antigen independent survival of peripheral 
blood cells (Correia, M.P. et al., 2009). Previous studies in monocytes showed that trypsin 
treatment caused a decrease in membrane bound IL-15 and the loss of IL-15R complex 
ability to bind IL-15-IgG2b fusion protein (Musso, T. et al., 1999). We suggest that IL-15 in 
hepatocytes is possibly bound to IL-15Rα, which trans-present IL-15 to effector cells. 
Thus, in this study we have uncovered an unexpected function for hepatocytes in 
maintaining the homeostasis of all NK subsets in the liver. Further studies are needed to 
determine how hepatocyte-derived IL-15 promotes the maintenance of NK cell 
populations in the liver. 
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As discussed earlier, obesity-associated pathologies decrease life expectancy and quality. 
Even though lifestyle changes, such as lower calorie intake and physical activity are quite 
helpful, medical and surgical interventions still remain as options for some people with 
morbid obesity. Moreover, NAFLD is treated by weight loss and therapies against insulin 
resistance or dyslipidemia. This means to treat either directly the hepatic steatosis or the 
pathological consequences. Of importance, although NAFLD is the most common liver 
disease in the US, no pharmacological therapies have been approved by the FDA so 
far(Tolman, K.G. and Dalpiaz, A.S., 2007). 
Our results propose a pathogenic role for IL-15 in NAFLD. Therefore, IL-15 could be 
potentially a novel target for developing new therapies against NAFLD. However, IL-15 is 
a non-dispensable player of antimicrobial immunity and any treatment affecting IL-15 
biology should take precautions into account (Kanegane, H. and Tosato, G., 1996; 
Stoklasek, T.A. et al., 2006). Lymphocytic infiltration in liver parenchyma and fibrogenesis 
characterizes most of liver disorders (Lalor, P.F. et al., 2007). Notably, we found that IL-15 
could contribute significantly to lymphocyte infiltration in fatty liver by modulating various 
chemokines. Given that chemokines are induced by IL-15 in hepatocytes in an IL-15Rα-
dependent mechanism, we propose that IL-15Rα in hepatocytes could be considered as a 
potential therapeutic target for NAFLD. 
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5. CONCLUSIONS 
 
Inflammation is frequently considered as a hallmark of obesity and non-alcoholic liver 
diseases. Several pro-inflammatory cytokines have been related to the development of 
obesity-associated pathologies. The current study was carried out to elucidate the role of 
IL-15 in the development of NAFLD. IL-15 is a pro-inflammatory cytokine, which is 
indispensable for the homeostasis of NK, NKT and memory CD8+ T cells. We showed that 
the gain in body weight and liver mass after 16 weeks of HFD are significantly reduced in 
Il15 null mice, which also displayed significantly reduced hepatic steatosis. Moreover, 
HFD increased the hepatic expression of IL-15 as well as others pro-inflammatory 
mediators, such as Tnfa and iNOS. In addition to reduced inflammatory response, Il-15 
deficient livers showed FA oxidation contributing to the observed decrease in fat 
deposition. 
Infiltration of immune cells plays an important role in liver inflammation and the 
development of NAFLD. HFD-induced macrophage infiltration of the liver was significantly 
decreased in the livers of IL-15 KO mice, which could be attributed to reduced hepatic 
expression of genes coding for the macrophage chemokines Ccl2 and Cxcl10. We also 
found that IL-15 stimulation induced the expression of Ccl5 and Cxcl10 genes in primary 
hepatocytes. These results suggest that the increased levels of IL-15 found in the liver of 
HFD-fed mice might stimulate hepatocytes to secrete chemokines, leading to immune cell 
recruitment and hepatic inflammation. 
We observed that HFD caused a significant increase in the total numbers of IHLs, and the 
NK cell populations and macrophage-derived IL-15Rα is needed for NKT cells 
homeostasis. Interestingly, we found that hepatocyte-specific expression of IL-15 Rα is 
indispensable for NK, NKT and iNKT cells maintenance in the liver. These findings 
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indicate that hepatocyte-derived IL-15 plays a major role in HFD-induced NAFLD via 
recruiting, maintaining and possibly activating the inflammatory cell populations such as 
macrophages and NK cells in the liver. These findings are illustrated in Fig. 5.1. 
 
 
 
 
Figure 5.1: IL-15 regulates immune cells recruitment and homeostasis in the liver. 
1) HFD induces Il15 over-expression in the liver. 2) IL-15 acts on hepatocytes and 
possibly other cells (KC, stellate cells) to induce chemokine secretion. 3) Chemokines 
recruit macrophages and NK cells cells to the liver. 4) IL-15 trans-presented by IL-15Rα in 
the hepatocytes or macrophages maintain NK and NKT populations in the liver.    
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